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Abstract
Chemokines are cell signalling proteins that promote cellular migration.
C-C motif chemokine ligand 2 (CCL2) plays an important role in the
inflammatory response, and is involved in the pathogenesis of diseases
such as asthma, atherosclerosis and cancer. The potential for modulation
of inflammatory processes via inhibition of chemokine interactions makes
CCL2 an attractive target for the development of novel anti-inflammatories.
In order to characterise these interactions – and the more general role of
chemokines within living systems – labelled chemokines are needed as tools
for use in biomedical research. Total chemical synthesis has previously been
used to produce site-specifically modified proteins (including chemokines)
incorporating a wide range of unnatural alterations such as fluorophores and
posttranslational modifications. Progress made towards the total chemical
synthesis of human CCL2 via Fmoc solid-phase peptide synthesis (SPPS) and
native chemical ligation (NCL) is described.
The microwave-assisted solid-phase synthesis of CCL2 as a single peptide
chain was found to be problematic due to hydrophobic aggregation,
and attempts to avoid this using the poly(ethylene glycol) (PEG)-based
ChemMatrix® support (in combination with pseudoproline dipeptides) are
reported. Progress has also been made towards a total chemical synthesis
utilizing NCL, and syntheses for two of the required fragments – the C-
terminal peptide acid CCL2(52-76) and a peptide thioester CCL2(12-35) – are
presented. While SPPS of the thioester was achieved using the sulfonamide
safety-catch linker, the use of the Dawson Dbz linker for the synthesis of
peptide thioesters was also investigated, and the results given here represent
the first reported use of the Dbz linker for microwave-assisted SPPS.
In addition, the structure determination of three analogues of a natural
product found to inhibit CCL2-mediated monocyte chemotaxis has been
carried out using single crystal X-ray diffraction data, thus contributing to
ongoing research aiming to elucidate the role of chemokine interactions in
biological systems.
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Chapter 1
Introduction
A complete grasp of the structure and interactions of a particular protein
within a biological system is key to understanding its function. A protein drug
target cannot be truly exploited, for example, without considering the nature
of its interactions with other elements of the signalling cascade or metabolic
pathway. By elucidating the three-dimensional structure of a biomolecule and
its sites of interaction with other proteins or ligands (using techniques such as
X-ray diffraction and protein NMR), molecules can be designed to manipulate
these interactions. Protein engineering is of crucial importance in the study of
proteins, as often it is only when a protein can be synthesized artificially – thus
modified or labelled versions can be produced – that its role can be thoroughly
characterised, indeed at the very least this may provide large enough quantities
for extensive biological assays or crystallographic analysis. Techniques such
as site-directed mutagenesis are central to biotechnology, and organisms such
as bacteria or fungi are classically used for the generation of modified proteins
for research. In contrast, the production of proteins via chemical synthesis is
an expanding field that provides a route to ‘customized’ proteins with greater
control and the potential for a broader range of modifications.
The total chemical synthesis of whole proteins offers a number of
advantages over conventional biosynthetic routes. While recombinant DNA-
based techniques utilizing expression systems such as Escherichia coli offer
some control over the primary sequence of the protein being produced,1 a
total chemical synthesis allows the site-specific incorporation of any number
of unnatural amino acids, labels (such as fluorophores2 or NMR probes3),
or any other suitably reactive chemical group into the target protein. An
application of particular interest is the selective generation of synthetic proteins
15
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with posttranslational modifications (PTMs), such as phosphorylations4 and
glycosylations.5 Furthermore, proteins of very high purity are accessible via
chemical synthesis, circumventing issues with conventional methods such
as endotoxin contamination.6 Despite the area of therapeutic glycoproteins
being the fastest growing field in the pharmaceuticals industry,7 glycosylated
proteins are not recombinantly expressed routinely in bacterial systems such
as E. coli,8 and the variability of glycosylation sites for recombinant protein
can render the successful purification of a desired glycoform impossible.7,9
Site-specifically glycosylated proteins can be obtained via chemical synthesis
however. Total chemical synthesis also allows the generation of racemic
proteins, potentially allowing more facile crystallization for X-ray diffraction
studies.10
Solid-phase peptide synthesis (SPPS) is a mature field, and peptides
with lengths of around 50 residues can now be routinely produced in high
yield using microwave-assisted solid-phase techniques and highly efficient
coupling reagents (vide infra). Linear syntheses of longer peptides can still be
problematic however, and a number of ligation strategies have been proposed
which allow access to larger peptides and proteins.11,12 Perhaps the most
influential of these is native chemical ligation, involving the condensation of
a peptide thioester and a second peptide containing an N-terminal cysteine,
with the subsequent S→N acyl shift generating a native amide bond (vide
infra).13
The chemokine CCL2 is a target of interest due to the role it plays in
a number of immune and inflammatory disease states including asthma,
rheumatoid arthritis, atherosclerosis and cancer.14 The 76 residue protein has
previously been shown to be accessible via chemical synthesis,15–19 allowing
the creation of analogues bearing site-specific modifications.20 The following
sections will review the target protein and explore various general aspects of
the chemical synthesis of whole proteins, concluding with a consideration of
the structure of the CCL2 molecule and its bearing on a potential synthetic
route.
1.1 Human C-C motif chemokine ligand 2 (CCL2)
Inflammation in response to damage of vascularized tissue is a complex
process involving a large variety of cell types and signaling molecules.21
16
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One particular reaction to injury (whether due to physical factors or infection
with a pathogen) is the movement of leukocytes from blood vessels into the
surrounding tissues in a process known as extravasation. The movement (or
chemotaxis) of leukocytes is promoted by so-called chemotactic cytokines, or
chemokines.
Chemokines, of which there are approximately 40 distinct types, act by
binding to G protein-coupled receptors (GPCRs) expressed on the surface of
leukocytes. A particular chemokine may bind multiple receptors – which in
turn are capable of binding many different chemokines – leading to a highly
complex code of chemotactic cues.21
1.1.1 CCL2 and extravasation of monocytes
One such chemokine – known as C-C motif chemokine ligand 2 (CCL2)∗ –
(Figure 1.1) has a role in the extravasation of monocytes (a particular class of
leukocyte). Monocytes can differentiate into macrophages or dendritic cells,
and play an important role in the response at a site of infection.21
In order to move from the blood into the tissues, monocytes must first
interact weakly with the apical face of epithelial cells comprising the blood
vessel walls. This interaction is mediated by selectins, a family of cell
adhesion molecules (CAMs) present on the endothelium and on the surface of
leukocytes, and results in rolling of the cells along the endothelial layer.25 The
next stage involves chemokine binding, and it is this that triggers both firmer
adhesion and the necessary cytoskeletal changes needed for extravasation to
occur.25 The process is illustrated in Figure 1.2.
In addition to receptor binding, CCL2 also binds to heavily sulfated
(and thus negatively charged) polysaccharides present on the endothelium
known as glycosaminoglycans (GAGs).21 This is thought to be important in
regulating local chemokine concentration, and for establishing a chemokine
concentration gradient that directs monocyte movement.27 It has been
suggested that chemokine oligomerization is essential for this process to
occur.28
∗Also known as monocyte chemoattractant protein-1 (MCP-1). The nomenclature relates
to the arrangement of two highly conserved Cys residues close to the protein N-terminus.22
17
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Figure 1.1: Ribbon representation of the CCL2 dimer (NMR solution structure).23,24
Figure 1.2: Stages of leukocyte extravasation: the moving cell initially rolls along
the surface of the endothelium (a process mediated by selectin interactions) before
adhering more strongly upon chemokine binding. Cell adhesion (resulting from
integrin/CAM interactions, not shown) leads to transmigration of the leukocyte
through the endothelium. The role of chemokine dimerization during this process
has not yet been clearly elucidated.26 Adapted from Lodish et al.21
18
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1.1.2 Therapeutic targeting of chemokine interactions
The myriad of chemokines and chemokine receptors – and their crucial
role in various biological processes and disease states – makes chemokine
interactions an attractive target for the development of new classes of
drugs.29 Variations in cell migratory behaviour can have dramatic effects
on a living system – indeed a link has been proposed between cytokine-
mediated chemotaxis and breast cancer metastasis30,31 – and the inhibition
of CCL2 protein-protein interactions (whether at the dimerization interface
or at receptor/GAG interaction sites) may be used to modulate inflammatory
processes for example. This would provide a new target for drug development,
potentially offering a route towards a novel class of anti-inflammatories.22 A
number of small molecule chemotaxis inhibitors are the focus of Chapter
5, while the intervening chapters deal mainly with the techniques used
to produce synthetic proteins (and hence tools with which chemokine
interactions can be studied). The following sections introduce the area of
peptide synthesis and its application to the total chemical synthesis of whole
proteins.
1.2 Chemical synthesis of proteins
1.2.1 Solid-phase peptide synthesis (SPPS)
Peptide synthesis in general involves the formation of an amide bond between
adjacent amino acids in a peptide sequence. The high temperatures needed to
react an amine with an unmodified carboxylic acid are generally incompatible
with the other reactive groups present on a peptide, and so a number of
activation strategies have been developed for efficient, high-yielding amide
bond formation.32 Many of these involve the in situ formation of a reactive ester
intermediate from the carboxyl terminus of the peptide, which subsequently
undergoes aminolysis upon treatment with the next amino acid to form a new
amide bond. This process is shown in Scheme 1.1.
Highly efficient amide bond formation is an essential aspect of peptide
synthesis, as even small yield losses (0.5-1%) at each step result in increasingly
low overall yields as the length of the target peptide increases. Despite
the development of effective coupling reagents however, the solution-phase
approach suffers from two major drawbacks. The first issue is the need to
19
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R OH
O activating agent
R OX
O
activation R NH
OR'NH2
aminolysis
R'
Scheme 1.1: General scheme for amino acid coupling via active ester formation.32
isolate and purify the coupling products at each step, which can be time
consuming. In addition, the inherent insolubility of the side chain-protected
peptide intermediates is often problematic at higher sequence lengths.13
The development of functionalized polystyrene resins by Bruce Merrifield
in the 1960s was a turning point for peptide synthesis.33 These resins (in the
form of insoluble beads decorated with reactive groups) act as a solid support
upon which a peptide can be anchored and elongated, enhancing solubility and
obviating the need for purification beyond simply washing the resin after each
step. When used in conjunction with efficient coupling reagents, solid-phase
strategies allow the synthesis of longer peptides than would be accessible in
the solution-phase, and peptides of greater than 100 residues can be routinely
produced using solid-phase peptide synthesis.34
Microwave assisted SPPS has been demonstrated to produce peptides and
proteins with dramatically reduced coupling times and improved crude prod-
uct purity when compared to conventional room temperature syntheses.35 The
technique has proved especially useful for ‘difficult’ sequences, such as those
liable to form β-sheet type structures during synthesis (vide infra). While it
has been suggested that there may be some peptide-specific microwave effect
that causes these beneficial effects – for example direct interaction of the
amide bond dipole with the electric field, leading to disruption of hydrophobic
aggregation (vide infra)36 – it is generally accepted that they are simply due to
the thermal effects also encountered during conventional heating.37
1.2.2 Convergent ligation: Accessing whole proteins
Despite becoming a commonplace technique for the synthesis of long peptides
and small proteins, conventional stepwise SPPS also suffers limitations on
target peptide length and can be problematic where long or particularly
troublesome protein sequences are desired (vide infra). Poor solubility of
the growing peptide chain is a major problem at higher sequence lengths, and
can result in low yields due to decreased availability of the reacting peptide
N-terminus.38 Another issue is the presence of deletion sequences arising
20
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from coupling steps that have proceeded in less than quantitative yield. While
these inevitable side products are often unproblematic with shorter targets,
the impurities generated increase with sequence length and can be difficult to
separate at the end of the synthesis due to their similarity to the target peptide.
As an alternative to the stepwise attachment of single amino acids onto
the growing peptide N-terminus, a so-called ‘convergent approach’ should
allow the design of a synthesis that maximizes the difference between ligation
product and impurities at each step (Scheme 1.2).39 Furthermore, with the
application of ligation chemistry that is tolerant of side chain groups, such
an approach could make use of unprotected peptide intermediates which are
freely soluble at millimolar concentrations in the presence of chaotropes†.13
A B A B C A B C A B C DD
A B
Stepwise approach
Convergent approach
C D
A B
C D
A B C D
Scheme 1.2: A convergent approach maximizes the difference between product and
impurities (unreacted starting materials) at each step, and allows reactions to be
carried out in parallel.
1.2.3 Native chemical ligation (NCL)
A particularly important tool with regards to the synthesis of large peptides
and proteins is ‘native chemical ligation’ (NCL). In this approach the side chain
thiol of an N-terminal cysteine of one peptide segment is reacted with a C-
terminal thioester formed on the other. A subsequent S→N acyl shift then
generates a peptide bond between the segments that is indistinguishable from
a ‘native’ amide linkage (Scheme 1.3). The sulfur chemistry utilized in this
method is compatible with the presence of reactive groups present elsewhere
†Additives that increase the solubility of the peptide chain, for example aqueous 6 M
guanidine·HCl.
21
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on the peptide segments (thioesters are more stable to hydroxide-catalysed
hydrolysis than their oxygen counterparts, while being more reactive towards
thiolysis/aminolysis), and so fully deprotected peptide intermediates can be
used.13 Some specific considerations are detailed in the following sections.
SR
O
H
N
R'O
H3N
H
N
O
HS
S
O
N
H
R'O
N
H2 O
H
N
H2O          pH 7
N
H
O
H
N
R'O
H
N
O
SH
Scheme 1.3: General mechanism for native chemical ligation.13
Thioester reactivity and catalysis
Conventional NCL typically makes use of alkyl thioesters which are relatively
unreactive, therefore requiring the presence of a catalyst with which to form
a more reactive thioester species in situ before ligation can occur. Commonly
used catalysts include a 1% benzyl mercaptan (1) / 3% thiophenol (2) mix, or
2-mercaptoethanesulfonate sodium salt (MESNa, 3) for recombinant peptide-
thioesters (Figure 1.3).40 Another catalyst, (4-carboxymethyl)thiophenol
(MPAA, 4), has also been proposed, being more effective and with a greater
water solubility and less offensive odour than those currently used.40
22
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SHSH SH
O
OH
HS
S
O O
O Na
MPAA,
MESNa,1 2
4
3
Figure 1.3: A selection of catalysts used in NCL.
Kinetic chemical ligation (KCL)
Another approach is to generate and purify reactive aryl thioesters separately,
for subsequent use in a ligation. This can be achieved via treatment of alkyl
precursors with an aryl thiol such as 4-mercaptophenylacetic acid.41 These
preformed ‘active’ thioesters will react preferentially over alkyl thioesters in a
multi-component ligation where catalyst is not present, and can therefore
be used for ligations in the N- to C-terminal direction.42 This is known
as ‘kinetically controlled ligation’ (KCL), and thioester segments with an
unmasked N-terminal Cys can be used in this approach without head-to-tail
cyclization occurring.
As an alternative to kinetic control, Shigenaga et al. used peptide thioacids
as ‘masked’ thioesters in order to carry out NCL in the N- to C-terminal
direction.43 Conversion of the thioacids to the corresponding thioesters and
subsequent NCL was accomplished in a one-pot matter.
N-terminal Cys thiol protecting groups
For stepwise ligations occurring in the C- to N-terminal direction, controlling
thioester reactivity is not an issue. Instead N-terminal Cys thiols must
be protected appropriately. Conventional approaches make use of the
acetamidomethyl (Acm) protecting group.44 The incorporation of a masked
Cys residue in the form of a thiazolidine has been demonstrated however,
with deprotection proving to be quicker, higher yielding and with fewer
manipulations required.45 The 1,3-thiazolidine-4-carboxyl (Thz) can be in-
troduced easily during SPPS using Boc-L-thiazolidine-4-carboxylic acid and
unmasked using 0.2 M methoxyamine hydrochloride (which has been used
23
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without damage to the thioester).42 Thz was utilized by Bang et al. in their
synthesis of the protein crambin.44,45 The synthesis is outlined in Scheme 1.4.
1-V15A SR
O
16-31 SR
OS
N
H 32-46
H2N
HS
i) NCL
ii) MeONH2·HCl
16-31 N
H
O
32-46
SH
H2N
HS
NCL
16-31 N
H
O
32-46
SH
N
H
SH
1-V15A
O
Scheme 1.4: Overview of the total chemical synthesis of [V15A]crambin.45
Photolabile protecting groups have also been used in native chemical
ligations. A phenacyl-type protecting group was introduced by Ueda et al.
in 2006, and was used successfully in a three-component one-pot NCL.46
Thioester formation
While a variety of methods exist for the formation of peptide C-terminal
thioesters,47 potentially the most convenient approach is to use a so-called
‘safety-catch’ linker compatible with Fmoc SPPS.‡ The sulfonamide safety-
catch48–50 is perhaps the best established technique for the solid-phase
synthesis of C-terminal peptide thioesters whereby the required peptide
‡SPPS utilizing amino acids N-terminally protected with the base-labile fluorenylmethy-
loxycarbonyl (Fmoc) protecting group.
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is synthesized on sulfamylbutyryl resin,§ with subsequent alkylation (using
iodoacetonitrile or trimethylsilyldiazomethane) and thiolysis resulting in
release of the thioester product (Scheme 1.5). This linker has been used
to produce peptide thioesters of up to 35 amino acids in length.47
H2N
S
N
H
OOO Fmoc SPPS
N
H
S
OOO
PeptideBoc
activation
N
S
OOO
PeptideBoc
R1
R1 = CH2CN or CH2TMS
thiolysis
O
Peptide SR2
Scheme 1.5: Thioester formation using the sulfonamide safety-catch linker.47
Potential problems associated with this method include racemization of
the C-terminal amino acid during lengthy loading reactions, aggregation of
the protected peptide, and side reactions during alkylation (minimized by
using TMS-CHN2).47 Ingenito et al. achieved high loadings with low levels
of epimerization through the use of amino acid fluorides for the initial linker
acylation.51 A significant increase in the yield of isolated thioester was reported
by Quaderer et al. when using 2 M LiBr/THF in place of DMF or THF as the
solvent during the thioesterification step.52 More recently the sulfonamide
linker was attached to an acid-labile resin and used to prepare peptide N-
alkylsulfonamides which could be used directly in ligation reactions to which
thiol was added.53
As an alternative to the sulfonamide safety-catch, the Dawson Dbz linker
can be used.54 This is a safety-catch linker for Fmoc SPPS that generates
N-acylurea peptides after treatment with p-nitrophenylchloroformate and
cleavage from the resin (see Section 3.2). The process is summarized in
Scheme 1.6. The N-acylurea peptides produced can be converted to a
thioesters in solution via treatment with thiol, or used directly for NCL.54
The N-acylurea moiety is also relatively stable to hydrolysis during storage,
§Available preloaded from Merk.
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and the products can be subjected to the acidic conditions often used during
HPLC purification (vide infra).54
N
H
Fmoc SPPS
cyclization
cleavage
O
FmocHN
H2N
N
H
O
HN
H2N
OPeptideBoc
N
H
O
N
N
H
O
OPeptideBoc
NH2
O
N
N
H
O
OPeptideH2N
Scheme 1.6: N-acylurea formation using the Dbz linker.54
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1.3 CCL2: Synthetic considerations
1.3.1 Structure and residues of significance
With respect to probe incorporation, three major interactions should be
considered:
• Receptor binding
• Glycosaminoglycan binding
• Chemokine oligomerization (and relevance to binding)
Although there are no receptor- or GAG-bound CCL2 crystal structures, a
number of studies have shown the importance of certain residues for receptor
binding and activity in vitro,19,55–58 and GAG binding in vitro28 and in vivo28,59
(summarized in Table 1.1).
Figure 1.1 shows a ribbon diagram of the CCL2 homodimer in solution.
A number of residues on the C-terminal α-helical domain are thought to be
important for GAG binding,28,59 while modification of the N-terminus has been
shown to be detrimental receptor binding and activity.19 Modification of the
N-terminal β-sheet domain may also be detrimental to activity as this region is
involved in H-bonding in the dimer (see Figure 1.1), therefore hindrance may
inhibit oligomerization and hence GAG binding ability (vide supra).
A probe should ideally be incorporated at a residue on the chemokine
surface, away from the proposed external binding and interaction sites
involved in these processes and also avoiding internal folding interactions.
The suitability of a potential site can be examined by consulting published
crystal structures15,61 or NMR solution structures23 to confirm the spatial
proximity of neighbouring residues. A representation of the CCL2 dimer is
shown in Figure 1.4, with biologically significant residues (listed in Table 1.1)
coloured red on one subunit (for the other the solvent-excluded surface is
shown). The high number of important residues towards the N-terminus,
and their role as part of the dimer interface, suggests that this would not be a
suitable region for probe incorporation. A more appropriate position would be
on the C-terminus – away from residues crucial for activity and those involved
in dimerization.
The protein primary sequence is given in Figure 1.5. Cys residues are
highlighted. A synthesis using NCL was developed by Grygiel et al. (vide
27
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Table 1.1: Residues of biological significance in the CCL2 primary sequence.
Residue number Amino acid(s) Biological significance (experiment)
1 Gln/Glpa Receptor binding and activityb in vitro
(diminished upon deletion/extension)19
2-8 PDAINAP Receptor binding and activity in vitro19,55,56
8 Pro Oligomerization (some evidence) in vivo28
10-13 TCCY Activity in vitro57
13 Tyr Receptor binding and activity in vitro28,55,58
18 Arg GAG binding in vitro28
19 Lys GAG binding in vitro28
24 Arg Receptor binding and activity in vitro,56,58
GAG binding in vitro28
28 Tyr Activity in vitro56
30 Arg Activity in vitro56
34 Ser Activity in vitro57
35 Lys Receptor binding and activity in vitro57,58
38 Lys Receptor binding58
49 Lys Receptor binding,58 GAG binding in vitro28
58 Lys GAG binding in vivoc
66 His GAG binding in vivoc
68 Asp Activity in vitro56
a Pyroglutamic acid. The N-terminal Gln can cyclize to form Glp in the mature
protein.16,60 Grygiel et al. incorporate this as a Glp residue directly in their
total chemical synthesis of CCL2 (vide infra).
b ‘Activity’ refers to in vitro cell chemotactic activity.
c Results of an in vivo study (intraperitoneal recruitment assay) - these residues
may be more essential for function than in vitro binding/activity studies
suggest.28,59
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C-terminus
N-terminus
Figure 1.4: CCL2 dimer with biologically important residues listed in Table 1.1
coloured red on one subunit (the N- and C-termini are also labelled).23,24 For the
other subunit the solvent-excluded surface62 is shown.
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infra) involving ligation at the central cysteine. Development of a 3- or 4-
segment NCL route may be useful as this would potentially allow the rapid
generation of chemokines labeled with different probe combinations.
...
...
Figure 1.5: CCL2 sequence showing disulphide bond connectivity.15
1.3.2 Previous total syntheses
Some total syntheses of CCL2 have already been published and are
summarized in Table 1.2. Although stepwise Fmoc SPPS approaches are
described, none of the syntheses published to date have used microwave
assistance. The general trend away from the use of Boc SPPS as a method of
chemically synthesizing whole proteins is due to the tendency of the harsh
conditions involved to degrade peptides (repeated TFA treatment), and the
risks associated with handling liquid hydrogen fluoride.63 Of the papers which
utilize stepwise Fmoc SPPS, only Kruszynski et al. give a yield for synthesis
of the linear peptide (30%). The group used affinity chromatography during
purification however, which required the use of a monoclonal antibody and
is hence a relatively expensive technique when compared to more commonly
used peptide purification methods such as RP-HPLC (Section 4.2). It was
decided that the approach explored for chemokine generation should be as
general as possible and with a low cost, therefore affinity chromatography
was deemed to be unsuitable for this purpose. The highest yield (60%)
was reported by Grygiel et al., who employed a two-segment NCL approach
utilizing pseudoproline dipeptides (Section 2.3.2). A linear stepwise synthesis
is conceptually simpler however, allowing the more rapid generation of
chemokines and chemokine analogues. Advances in microwave SPPS means
30
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that attempting this is now feasible, and it is for this reason that a stepwise
approach was explored initially (Chapter 2).
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Table 1.2: Previous total syntheses of CCL2.
Authors Year Approach Yielda /% Additional details
Grygiel et al.15 2010 NCL (segments synthe-
sized via Fmoc SPPS)
60 Pseudoprolinesb were incorporated to disrupt β-
sheet structure and improve solvation (leading to
increased yield).
Kruszynski et al.16 2006 Stepwise Fmoc SPPSc 30 Affinity chromatography was used for purification
(in addition to HPLC). The method was used to
produce site-specific biotinylated analogues.20
Reid et al.17 2006 Stepwise Fmoc SPPS - -
Brown et al.18 1996 Stepwise Fmoc SPPSd - The Tbfmoc protecting group was used to
aid HPLC purification (high hydrophobicity and
characteristic absorption).
Gong and Clark-Lewis19 1995 Stepwise Boc SPPSe - -
a Linear peptide after purification (before oxidation and folding).
b Dimethyloxazolidine dipeptides can be used in place of Ser or Thr and are best incorporated at intervals of approximately
six residues.64 (Acid-mediated ring opening regenerates Ser and Thr during the TFA resin cleavage step.)
c Significantly decreased product quality was reported with double coupling/capping protocol over single coupling.
d Utilizing double coupling/capping.
e SPPS utilizing amino acids N-terminally protected with the acid-labile tert-butoxycarbonyl (Boc) protecting group.
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1.4 Summary
It can be seen that CCL2 is a biologically relevant and synthetically accessible
target protein. A range of techniques in peptide synthesis (such as SPPS
and NCL) have been described and will be utilized in attempts to synthesize
CCL2 chemically, enabling the generation of CCL2 analogues bearing site-
specific modifications. These will be useful as tools for investigating the role
and biomolecular interactions of the chemokine in biological systems, and to
evaluate its potential as a drug target.
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Linear stepwise synthesis
When considering the application of total chemical synthesis to a protein of
biological interest, two major factors should guide the choice of approach –
namely the speed and simplicity of the synthesis, and the ease with which
it can be used to produce site-specifically modified analogues of the target
molecule. A linear stepwise synthesis – that is, one in which the target is built
one amino acid at a time as a single peptide strand – is conceptually simpler
than a strategy involving native chemical ligation (vide infra). The stepwise
approach nonetheless affords comparable control over the incorporation of
modifications, while circumventing many of the difficulties associated with
NCL (thioester generation, optimization of ligation conditions etc).
With regards to CCL2, a synthetic route should ideally allow the rapid
generation of labelled chemokines, and for this reason a linear stepwise
approach was initially adopted.
2.1 Initial considerations
The complete human CCL2 target sequence is shown in Figure 2.1. A
schematic indicating secondary structure assigned from crystal structure
data15 using Kabsch and Sander’s DSSP algorithm65 is also shown. Information
of this type is especially relevant as formation of β-sheet secondary structure
during a synthesis can lead to aggregation of the peptide chain resulting in
poor coupling efficiencies.37 For this reason it was anticipated that difficulties
would be encountered upon reaching the β-sheet regions shown.
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The software utility Peptide Companion – a powerful tool used for the
prediction of sequence difficulties – was also utilized.66 Difficult coupling steps
predicted for the CCL2 primary sequence (based on calculated aggregation
potentials) are summarized in the graph shown in 2.1. A potentially
problematic section can be identified between Lys-49 and Lys-38, which
coincides with the start of the first region of β-sheet secondary structure.
36
QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT
1 10 20 30 40 50 60 70
1159.8 [M + H]+2827.5 [M + H]+4373.2 [M + H]+
~4700 (4700.44)
(6547.58)(8556.85)
(8684.98)
Figure 2.1: CCL2 primary sequence and secondary structure assignment.15,65 α-Helical regions and β-sheets are represented by
cylinders and arrows respectively. Experimental m/z values are also shown for points in the synthesis where intermediate MALDI-
TOF MS analysis resulted in meaningful data (see Figure 2.3, Section 2.2). Calculated values are given in brackets, including
those expected for test cleavages where no molecular ion peak was observed in the spectrum (vide infra). A representation of
‘sequence difficulty’ is also shown in the form of a plot of calculated aggregation potential against residue number obtained using
the Peptide Companion software.66 Difficulties are predicted in the synthesis for those residues with potentials above 1.2 (shown
in black) – a problematic region (coinciding with β-sheet secondary structure) is clearly predicted between Lys-49 and Lys-38.
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2.2 Microwave synthesis using polystyrene resin
A stepwise approach utilizing solid-phase Fmoc chemistry was first adopted.
It was thought that microwave assistance would increase the efficiency
of the coupling and deprotection steps, decreasing reaction times and
improving on the crude product yield and purity attained in previous literature
syntheses.15–18 It was hoped that this type of approach would allow the
development of a rapid, easily reproducible synthesis in accordance with the
aims discussed.
2.2.1 The solid support: Handling, polymer choice and
linker types
Initial MW-SPPS runs were attempted utilizing polystyrene Wang resin, a
support traditionally used for the solid-phase synthesis of peptide acids. The
structure of the Wang linker is shown in Figure 2.2 alongside some other
linkers routinely used for Fmoc SPPS. Here it is important to emphasize the
distinction between the linker type (Wang) and the resin polymer (polystyrene)
– careful selection of both is crucial for an efficient synthesis. Commonly used
polymers include polystyrene, poly(ethylene glycol) (PEG), and polyamide
(PA), each with different swelling properties in various solvents.67 For the
linkers shown in Figure 2.2 either a hydroxyl group (for a so-called ‘acid
resin’) or amine group (‘amide resin’) on the linker is used to anchor the
C-terminal amino acid onto the resin via an esterification or amide bond
formation respectively during the initial resin loading. After elongation the
peptide is cleaved from the resin using 95% trifluoroacetic acid (TFA) to give
either a peptide acid or peptide amide (depending on whether an acid or amide
resin is used).∗
As diffusion rates of reagents into the polymer matrix largely dictate
reaction kinetics in solid-phase synthesis, only light agitation of the reaction
is required.67 The use of magnetic stirrers should be avoided so as not to
crush the resin beads – gentle shaking of the reaction vessel or bubbling
using a stream of nitrogen is recommended. Effective swelling of the polymer
support in the reaction solvent is also vital, as the resin bead surface represents
only 1% of coupling sites on the resin.67 For optimum results pre-swelling in
∗Many other linker types exist giving different C-terminal functionalities upon cleavage in
various conditions.68
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NH2OMe
MeO O
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Rink amide
HMPBWang
Figure 2.2: Commonly used linkers for Fmoc SPPS.67 For Rink amide the C-terminal
amino acid is attached via coupling to an amine, for Wang and HMPB a hydroxyl
group is used. Peptide cleavage from the resin is carried out using 95% TFA for all
of the above linkers to give peptide amides or peptide acids depending on the linker
type (see text).
dichloromethane (DCM) overnight is preferred, although swelling for 1 h
beforehand in DCM, DMF or a mixture of both was found to be adequate for
most applications. DMF was used as the reaction solvent for all SPPS carried
out due to its favourable swelling properties and suitability for MW heating
(low volatility and high relative permittivity).69
2.2.2 Automated SPPS
Wang resin was purchased from Novabiochem preloaded with the amino acid
threonine, the C-terminal residue of CCL2. Preloaded resin was used in order
to circumvent problems typically associated with the esterification required
for resin loading, such as racemization.67 A resin with a low substitution (0.27
mmol/g) was chosen as it was anticipated that effects from steric hindrance
and aggregation would be more significant the larger the target peptide.
Stepwise syntheses were run on an CEM Liberty1 automated peptide
synthesizer equipped with a Discover microwave. Single couplings were
carried out with activation (vide infra) using 5 equivalents of Fmoc amino acid
under the default conditions (75 ◦C, 10 min). Removal of the Fmoc group
was effected via treatment with 20% piperidine for 3 min with microwave
assistance (75 ◦C).
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Characterisation of peptide intermediates cleaved from the resin at
various points during the synthesis was carried out using MALDI-TOF mass
spectrometry (see Section 2.2.3). Mass spectra showing the products of a
number of test cleavages are shown in Figure 2.3. While synthesis up to Ala-
53 is clearly achievable (24-mer), there is an apparent reduction in the purity
of the intermediate obtained on reaching Glu-39 (38-mer). Continuation of
the synthesis past Cys-36 did not yield crude products of the correct molecular
weight observable by MALDI-TOF MS. Isolation of the complete chemokine
from the crude product mixture was attempted using high resolution FPLC
(Section 4.2) but no species above ∼6 kDa was observed in any of the column
fractions. Syntheses were performed using three different coupling reagents:
PyBOP®,70 HBTU71 and TBTU72 (Figure 2.4). No significant difference in
reaction efficiency was observed between reagents.
It was suggested that the difficulties encountered upon reaching Glu-39
may result from aggregation of the peptide during synthesis, leading to a
reduction in solubility of the growing peptide and increased steric hindrance
at the N-terminal amine.37,73 It is therefore perhaps unsurprising that the
problems described arise after Ala-53, where the first region of β-sheet
secondary structure begins (Figure 2.1). In light of this it was decided that an
alternative resin polymer should be sought, which would be more suitable for
the synthesis of long peptides via SPPS (vide infra).
2.2.3 Synthesis monitoring and characterisation
The most commonly used technique for confirming the presence of the desired
peptide sequence during SPPS is MALDI-TOF mass spectrometry (see Section
4.1 for more detail). In addition to the characterisation of the final product after
cleavage from the resin, MALDI-TOF MS analyses can be run on small-scale
‘test’ cleavages carried out on samples of peptide-resin taken at intermediate
points during the synthesis. Samples for test cleavage be taken after any
step in a manual synthesis, and the Liberty1 software allows modification of
reaction cycles to incorporate a pause at any reaction step (allowing access to
the reaction vessel during an automated SPPS run).
For manual syntheses (vide infra), qualitative colourimetric tests provide
a cruder (but far less time-consuming) method of confirming whether a
particular coupling or deprotection step has been successful. The tests
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Figure 2.3: MALDI-TOF mass spectra resulting from analysis of test cleavage products
obtained at various points during an attempted stepwise synthesis of CCL2(1-76) –
5 (full sequence) – via MW-SPPS. Synthesis up to Ala-53 (fragment 6) is feasible
using polystyrene Wang resin (spectrum A), although difficulties are encountered
upon reaching Glu-39 (B). A broad molecular weight distribution due the presence
of deletion peptides (indicating synthesis inefficiency) is observed at Cys-36 (C).
Continuation of the synthesis did not yield any products of the correct molecular
weight upon completion (D).
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Figure 2.4: The coupling reagents PyBOP®, HBTU and TBTU. The last two differ only
in their counterion, which has no influence on the reactivity.32
summarized in Table 2.1 can be carried out on resin-bound peptide directly,
without the need for cleavage from the support.
Table 2.1: Qualitative tests for the presence of free amines.63
TNBS Test74 Acetaldehyde/Chloranil
Test75
Procedurea 1% TNBS in DMF and 10%
DIPEA in DMF
2% acetaldehyde in DMF
and 2% chloranil in DMF
Positive resultb Red Dark blue/green
Negative resultb Grey/yellow Colourless/yellow
Additional details Primary amines only For the detection of
secondary (and primary)
amines
a Reagents to be added in equal amounts to a sample of the resin (see
Experimental section).
b Colouration of the resin beads themselves. Observation under a microscope
may be required in ambiguous cases.
2.3 ChemMatrix® resin: A PEG-based support for
SPPS
The significant loss of coupling efficiency observed during attempts thus far
to synthesize CCL2 on-resin in a single run (Section 2.2) was suspected to be
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the result of aggregation of the peptide or steric hindrance at the N-terminus
during coupling and deprotection steps. It was therefore decided that an
alternative resin polymer should be sought which would be more suited to
the assembly of long peptides and proteins via SPPS.
ChemMatrix® is a PEG-based solid support73 that has been utilized for the
synthesis of long and/or difficult sequences – including β-amyloid peptide,76
HIV-1 protease77 and the chemokine CCL578† – via SPPS. The amphipathic
nature of PEG – due to its ability to form a number of helical structures of
varying hydrophobicity – ensures the resin is well-solvated (and hence swells
effectively) in a range of polar and nonpolar solvents.73 A low molecular
weight PEG was even demonstrated to act as the solvent when utilized as the
solid support and melted during a MW-assisted reaction where no additional
solvent was present.79 Crucially, ChemMatrix® swells better than polystyrene
in DCM and DMF, the most effective solvents for swelling polystyrene-based
resins.73
2.3.1 MW-SPPS using ChemMatrix® resin
An automated microwave synthesis was attempted using ChemMatrix®
HMPB‡ resin purchased from Sigma-Aldrich. As with the previous synthesis,
resin preloaded with the C-terminal Thr residue was used. A test cleavage was
carried out upon reaching Ala-53, yielding peptide 6 which was previously
shown to be easily accessible using polystyrene Wang resin (Figure 2.3). The
mass spectrum of the cleavage mixture is given in Figure 2.5. The crude
product from the ChemMatrix® synthesis appears to be of poorer quality, and
the major peaks present can be assigned to deletion sequences.
The apparent failure of the synthesis of such a short peptide was
hypothesized to be at least partly due to degradation of the PEG support under
microwave conditions.79,80 Before attempting a room temperature synthesis
however, it was deemed necessary to address the problem of hydrophobic
aggregation.
†The synthesis of CCL5 also made use of pseudoproline dipeptides (vide infra).
‡For linker structure see Figure 2.2.
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Figure 2.5: MALDI-TOF mass spectrum of test cleavage mixture from MW
synthesis of CCL2 up to Ala-53 using ChemMatrix® resin. While target peptide 6
(ADPKQKWVQDSMDHLDKQTQTPKT) is present, the purity of the crude product
appears poorer than that of the corresponding intermediate in the previous synthesis
(Figure 2.3, spectrum A).
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2.3.2 Disrupting aggregation using pseudoproline dipep-
tides
The problems encountered during the attempts described thus far to
synthesize CCL2 on polystyrene Wang resin were largely attributed to
hydrophobic aggregation exacerbated by the tendency of the peptide to
form regions of insoluble secondary structure. ’Pseudoproline’ dipeptides
(or oxazolidine dipeptides) have been shown to be a useful tool to increase
synthesis yields for difficult β-sheet-rich sequences where aggregation is an
issue.64,81 These preformed cyclized dipeptides of Ser/Thr and another amino
acid (Scheme 2.1) are available commercially, and can be incorporated during
a synthesis using standard Fmoc SPPS conditions. The cyclic oxazolidine
moiety is isosteric with proline, hence the incorporation of pseudoprolines
can disrupt the formation of secondary structure such as β-sheets. In some
cases pseudoprolines have enabled the synthesis of proteins where SPPS runs
have otherwise failed completely to generate any product.82
For optimal effect pseudoprolines should be separated from each other and
from Pro residues by a distance of 5 or more amino acids, with a minimum
separation of 2 amino acids.82 On inspection of the CCL2 primary sequence
it was found that the spacing of Pro, Ser and Thr residues was ideal for the
incorporation of pseudoproline dipeptides.15§
Microwave-assisted synthesis
A manual MW-assisted synthesis utilizing preloaded ChemMatrix® resin
and pseudoproline dipeptides was attempted. Reactions were run under
identical conditions to the automated syntheses (except where detailed
in the Experimental section), with microwave heating carried out using a
Discover microwave. Test cleavage mass spectra from various points in
the sequence are shown in Figure 2.6. Sites of pseudoproline inclusion
are also indicated. Successful incorporation of the first pseudoproline was
demonstrated (spectrum B), as well as synthesis up to Gln-61 (16-mer, using
the second pseudoproline) – although the product peaks for the intermediate
reached at this stage are very small (spectrum C).
§Positioning as follows: QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPK
EAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT.
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Figure 2.6: MALDI-TOF mass spectra for test cleavages at various points in the
partial MW synthesis of CCL2 utilizing pseudoproline dipeptides (on CM resin). Bold
underlined residues represent sites where pseudoproline dipeptides were included.
Both pseudoprolines are incorporated successfully, although the product peaks
observed upon reaching Gln-61 are very small (C).
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Scheme 2.1: Pseudoproline dipeptides (of the form XS or XT, where X is another
amino acid) can be incorporated via Fmoc SPPS and undergo acidolysis during the
TFA cleavage step to generate the uncyclized dipeptide.64 The Fmoc-protected serine
dipeptide building block is shown (side chain of X represented by R group).
Room temperature synthesis
A room temperature synthesis (utilizing pseudoprolines) was also carried out
to investigate whether microwave irradiation may be playing a part in the
apparent loss of product quality observed with CM resin. Automated couplings
were run at room temperature on the Liberty1/Discover system, with single
couplings lasting 1 h and deprotections performed in two steps (5 min then
10 min – see Experimental section for full details).
Test cleavage mass spectra are shown in Figure 2.7. When compared with
corresponding analysis from the MW synthesis, the spectrum obtained upon
reaching Gln-61 (D) contains sharper, more clearly defined peaks of higher
intensity – although only deletion sequences are observed in the cleavage
mixture. From this result it can perhaps be suggested that while MW assistance
does help to improve reaction efficiency (thereby decreasing the occurrence
of deletions), the apparent yield of the crude product suffers when CM resin is
subjected to microwave conditions (as tentatively inferred from MALDI-TOF
MS data). It is therefore recommended that ChemMatrix® acid resins should
not be used for SPPS with microwave heating.
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Figure 2.7: MALDI-TOF mass spectra for test cleavages during synthesis of part
of CCL2 at room temperature using pseudoproline dipeptides (on CM resin).
Pseudoproline incorporation at the points shown (bold underlined) was successful,
although only peaks belonging to deletion peptides are observed in the spectrum
obtained upon reaching Gln-61 (D).
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2.4 Summary
The stepwise synthesis of CCL2 as a single peptide has been attempted using
polystyrene Wang resin with microwave assistance. While elongation past
Glu-39 proved problematic (potentially due to hydrophobic aggregation of the
peptide on-resin), synthesis up to Ala-53 was shown to be achievable under
these conditions. The PEG-based ChemMatrix® resin was investigated as an
alternative support that may be better suited to the synthesis of the (relatively
large) target protein, although initial MW-SPPS attempts using CM resin were
disappointing. The use of pseudoproline dipeptides appeared to increase
crude product quality however, suggesting that the ‘sequence difficulties’
experienced were at least in part due to hydrophobic aggregation. It was
found that room temperature synthesis conditions were perhaps more suitable
when using CM resin, although the lack of microwave assistance resulted in
deletions that need to be eliminated via the use of a double coupling protocol.
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Towards native chemical ligation
The attempts at a stepwise linear synthesis described in the previous section
highlight the obstacles often encountered during the solid-phase synthesis
of long peptides. Of these, two problems – namely aggregation on-resin
(leading to loss of coupling efficiency) and difficulties separating the end
product from similar deletion sequences (see Chapter 4) – can be avoided
by adopting a strategy in which shorter segments of the target are synthesized
and ligated in solution. One such ligation technique, ‘native chemical ligation’
(Section 1.2.3), utilizes the transthioesterification of a peptide thioester with a
thiol ligation partner (followed by an S→N acyl shift) to form an amide bond
between two fully deprotected peptides in aqueous solution.
Due to the lack of success with attempts to assemble the whole of CCL2
on-resin as a single peptide, it was thought that a convergent approach utilizing
NCL would be promising as an alternative strategy for the total synthesis of
CCL2. An evaluation of two methods of thioester generation, as well the
synthesis of a number of thioester segments and a Cys ligation partner are
described in the following sections.
3.1 Proposed synthesis using NCL
Scheme 3.1 outlines a proposed (fully convergent) strategy for the total
chemical synthesis of CCL2 (5) via NCL in 4 segments. The ligation of
fragments 6 and 7 is kinetically controlled (the aryl thioester of 6 should
react preferentially over the alkyl thioester of 7), and the N-terminal Cys of
fragment 8 is masked as a thiazolidine during the the ‘conventional’ ligation of
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8 and 9. The two ligations described can be performed in parallel, potentially
allowing rapid generation of CCL2 analogues (cf. a stepwise approach with
ligations occurring in the C- to N-terminal direction). Ligation of the resulting
segments (10 and 11) affords the full chemokine.
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Scheme 3.1: Fully convergent 4-segment total chemical synthesis of CCL2 utilizing NCL. The ligation of fragments 6 and 7 is
kinetically controlled (see text). 6 is an aryl thioester, and ’Ar’ represents an electron withdrawing aromatic group such as phenyl.
The N-terminal Cys of fragment 8 is masked as a thiazolidine.
53
Towards a total chemical synthesis of human CCL2
3.2 The N-acylurea approach for the synthesis of
peptide thioesters
Although the number of Fmoc SPPS strategies for producing peptide thioesters
has grown dramatically in recent years,47 none are as established as
conventional methods for the generation of peptide acids and amides, and
hence no single approach has emerged as the dominant technique for peptide
thioester generation. Strategies utilizing the so-called ‘safety-catch’ principle
(Section 1.2.3) offer convenient methods for obtaining peptide thioesters
directly using SPPS, and it was therefore decided that these would be the
best option for producing the thioester segments required for the synthesis of
CCL2 via NCL.
The N-acylurea approach introduced in 2008 by Blanco-Canosa and
Dawson utilizes an acid-labile linker modified with 3,4-diaminobenzoic acid
(Dbz) onto which a peptide chain can be assembled.54 Treatment with p-
nitrophenylchloroformate forms the cyclic N-acylurea moiety (also known as
an N-acyl-benzimidazolinone, Nbz), which can be cleaved under standard
conditions to give peptides incorporating a C-terminal Nbz group. These Nbz-
peptides can be converted to thioesters in solution or used directly in ligation
reactions.54
3.2.1 Suitability of the Dbz linker for MW-SPPS
The synthesis of initial test fragment 12 – CCL2(42-51)N-acylurea (Scheme 3.2)
– was attempted using MW-SPPS and Dawson Dbz AM∗ resin available from
Novabiochem. The 10-residue sequence was assembled using standard
automated MW conditions (see Experimental section), with Boc-protected
isoleucine coupled as the final amino acid to protect the N-terminus during
the subsequent linker activation and cyclization. Synthesis monitoring via
cyclization of a sample of peptide-resin followed by cleavage of N-acylurea
intermediates is unfeasible using this approach, as the resin-bound peptide
cannot be elongated once the necessary N-terminal Boc group has been
incorporated. Nevertheless, cleavage of the Rink amide linker without
prior activation/cyclization releases diaminobenzamide-peptides that can be
∗Aminomethyl. AM resin (effectively polymer-bound benzylamine) is a support used in
solid-phase synthesis. Dawson Dbz AM resin comprises Dbz linked via the Rink amide linker
to an aminomethylpolystyrene support (one Dbz amine is Fmoc-protected).
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observed (for example 13, Scheme 3.4), hence allowing chain elongation to
be followed easily by small-scale cleavage of resin-bound peptides without
N-terminal Boc protection. This is an advantage over the sulfonamide linker,
which is not acid-labile and must be cleaved via attack by a thiol nucleophile
(vide infra).
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Scheme 3.2: Synthesis of Nbz-peptide 12 using Dawson’s N-acylurea approach. Side
chain protecting groups are not shown. Structure 18 is a putative branched product
produced as a result of linker over-acylation (see text). Reagents and conditions: (i)
Fmoc MW-SPPS (see Experimental section); (ii) p-nitrophenylchloroformate (5 equiv),
DCM, rt, 1 h; (iii) DIPEA, DMF, rt, 45 min; (iv) TFA (95%, water), TIPS, rt, 4 h.
Activation and cyclization of resin-bound product 15 were carried out via
treatment with 5 equivalents of p-nitrophenylchloroformate for 1 h, followed
by 0.5 M DIPEA for 45 min. The resultant peptide was cleaved from the resin
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using standard TFA cleavage conditions and analysed via MALDI-TOF MS. No
peak corresponding to 12 (Mr = 1320.6) was observed in the mass spectrum,
and the major peaks (Figure 3.1, spectrum A) correspond to protonated and
sodiated versions of a species that is ∼400 Da greater than the mass of the
target peptide (m/z = 1736.2 and 1757.8 respectively).
1700 1750
m/z
0
50
100
150
200
250
In
te
n
si
ty
1757.8, [M + Na]+
1736.2, [M + H]+
400 500 600 700 800 900 1000 1100 1200
m/z
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
55000
In
te
n
si
ty
950.6
879.6
780.5
667.4
566.3
- A
-V
- I
- T
1000 1500
m/z
0
200
400
600
800
1000
1200
In
te
n
si
ty
1378.7, [M + Alloc + H]+
1294.7
[M + H]+
A B
C
Figure 3.1: MALDI-TOF mass spectra for attempts to synthesize CCL2(42-51) N-
acylurea (12) using Dawson Dbz AM resin under various conditions. Spectrum A
shows the products of the initial MW-assisted synthesis: the target sequence is
not present, although peaks corresponding to putative structure 18 (Scheme 3.2)
are observed (resulting from ‘over-acylation’, see text). For the subsequent room
temperature synthesis (B) only a series of deletion peptides are present. MW-SPPS
using an Alloc-protected linker (spectrum C) produces the correct peptide sequence
with no branching (although the desired N-acylurea species is not observed, see text).
SPPS using the Dbz linker relies on the fact that after coupling of the
C-terminal amino acid to the first linker amine group, steric and electronic
factors generally prevent reaction at the second.54 Reaction at both groups
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is nevertheless possible, and so-called ‘over-acylation’ has been observed
for sequences rich in sterically unhindered residues such as glycine.83 This
results in the formation of branched products that cannot be cyclized to form
the required N-acylurea, and it was suspected that the major peaks observed
in the mass spectrum were due to the presence of a branched product such
as 18 (m/z = 1736.2), shown in Scheme 3.2.
Despite tentatively assigning the observed signals, it was nonetheless
surprising that over-acylation should be observed for a sequence comprising
only sterically hindered residues. Given the success of previous syntheses
utilizing the Dbz linker carried out at room temperature,84–86 it was suggested
that MW conditions may promote reaction at the second linker amine even
for hindered amino acids. To test this, a second automated synthesis was run
at room temperature – the MALDI-TOF mass spectrum is given in Figure 3.1
(spectrum B).
Peptide 12 is once again absent from the spectrum, although in this
case the observed signals have m/z values lower than expected, suggesting
that they perhaps correspond to deletion sequences rather than branched
products. Furthermore, a series of deletions (shown on spectrum) can clearly
be linked to the peak with m/z = 950.6, indicating that the major signal
corresponds to a peptide containing those residues. These results suggest
that while MW conditions promote over-acylation of the Dbz linker, a protocol
utilizing room temperature single couplings is not sufficient for the synthesis
of this sequence. In light of the benefits afforded by MW assistance, it was
decided that developing a modified Dbz strategy for use in MW-SPPS would
be preferable to optimizing the room temperature synthesis.
3.2.2 Preventing over-acylation
As over-acylation is caused by unwanted coupling of amino acids onto both
linker amines, it was suggested that protection of one of the amine groups
would prevent the formation of branched products, hence allowing use of the
Dbz linker for MW-SPPS. Mahto et al. previously demonstrated the use of the
allyloxycarbonyl (Alloc) protecting group for this purpose, with elimination of
over-acylation when an Alloc-protected resin was used.83
The free amino group of Fmoc-protected Dbz resin was first Alloc-
protected by treatment with allyl chloroformate and DIPEA for 24 h
(Scheme 3.3). Complete protection was monitored qualitatively using the tests
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described in Section 2.2.3. After removal of the Fmoc group, the C-terminal
isoleucine residue was double coupled using the coupling reagent HATU and
15 equivalents of Fmoc-Ile-OH. These conditions were required as coupling
onto the Alloc-Dbz linker was found by Mahto et al. to be inefficient for the
β-branched hydrophobic amino acids Ile and Val.83 Unreacted amine groups
were then capped via acetylation with acetic anhydride and the sequence
CCL2(42-51) assembled on the resin via MW-SPPS.
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Scheme 3.3: Alloc protection and loading of the Dbz linker. Reagents and conditions:
(i) allyl chloroformate (10 equiv), DIPEA (1.0 equiv), DCM, rt, 24 h; (ii) 20% piperidine,
DMF, rt, 2 × 10 min; (iii) Fmoc-Ile-OH (15 equiv), HATU (13.5 equiv) and DIPEA (27
equiv), DMF, rt, 2 × 1 h; (iv) 20% acetic anhydride, DMF, rt, 30 min.
Removal of the Alloc group was carried out via treatment with Pd(0) and
PhSiH3 (Scheme 3.4), and linker activation and cyclization were carried out
as described previously. The mass spectrum resulting from analysis of the
TFA cleavage mixture is shown in Figure 3.1 (spectrum C). While no peak
corresponding to an N-acylurea species is observed, the uncyclized species
present – deprotected 13 (m/z = 1294.7) and Alloc-protected 22 (m/z =
1378.7), Scheme 3.4 – are unbranched (no over-acylation) and complete
(no deletions), demonstrating that MW-assisted synthesis of this sequence is
feasible using the Dbz linker. Although the Alloc deprotection and cyclization
issues need to be addressed, to the best of our knowledge this represents the
first reported use of the Dawson Dbz linker for microwave-assisted SPPS.
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Scheme 3.4: Removal of the Alloc group from the Dbz linker. Reagents and
conditions: PhSiH3 (20 equiv), Pd(PPh3)4 (0.35 equiv), DCM, rt, 30 min. Uncyclizedproducts 13 and 22 (m/z = 1294.7 and 1378.7 respectively - spectrum C, Figure 3.1)
observed following TFA cleavage from the resin are also shown.
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3.3 Thioester generation using the sulfonamide
safety-catch linker
Alongside attempts to synthesize peptide thioesters using the Dbz linker, the
well-established ‘sulfonamide safety-catch’ approach was also investigated.
This method circumvents problems associated with over-acylation, but does
not form intermediate N-acylurea peptides (as the thioesters are produced
directly). In addition to thiols, the linker can be attacked after activation with
a variety of other nucleophiles50 to produce peptides with various C-terminal
functionalities (such as amides87 and esters88) or the N-terminus of the peptide
itself89 (head-to-tail cyclization). The sulfonamide linker was used by Grygiel
et al. to generate peptide thioesters used in their synthesis of CCL2 via NCL.15
3.3.1 Trial synthesis and optimization of deprotection con-
ditions
An automated room temperature synthesis of fragment 24 – CCL2(26-35)
thioester (Scheme 3.5) – was attempted in order to investigate the usefulness
of the sulfonamide linker for producing peptide thioesters. The peptide was
assembled using standard room temperature conditions (see Experimental
section) on sulfamylbutyryl resin, with Boc-Ala-OH coupled as the N-terminal
amino acid. As with the Dbz linker (Section 3.2.1), the Boc group is essential
to prevent alkylation of the N-terminus during the subsequent activation step.
In contrast to the N-acylurea approach however – which utilizes the acid-labile
Rink amide linker facilitating rapid analysis of peptide intermediates – peptides
anchored to the sulfonamide linker can only be released via treatment with an
alkylating agent followed by attack with a thiol nucleophile (each step ∼24 h).
This limits the feasibility of convenient synthesis monitoring via small-scale
test cleavages when using the sulfonamide safety-catch approach.†
Linker activation was carried out via alkylation of the N-acylsulfonamide
with iodoacetonitrile (24 h), followed by treatment with thiol (ethyl 3-
mercaptopropionate) and sodium thiophenolate catalyst (24 h) in order to
†A solution to this problem is to anchor the safety-catch to the resin via an acid-labile
linkage such as Rink amide (see Section 1.2.3). Preloaded sulfamylbutyryl resin (without Rink
amide linker) is commercially available and was used due to the difficulties associated with
sulfonamide loading.51,53 During the writing of this report however, a number of preloaded
sulfamylbutyryl Rink amide resins were made available to order from Novabiochem.
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Scheme 3.5: Synthesis of peptide thioester 24 using the sulfonamide safety-catch
approach. Side chain protecting groups are not shown. Reagents and conditions: (i)
Fmoc MW-SPPS (see Experimental section); (ii) ICH2CN (10 equiv), DIPEA (10 equiv),DMF, rt, 24 h; (iii) ethyl 3-mercaptopropionate (50 equiv), PhSNa (0.5 equiv), DMF,
rt, 24 h; (iv) TFA (95%, water), TIPS, rt, 4 h.
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generate protected peptide thioester 28 (Scheme 3.5). The standard global
deprotection conditions (95% TFA/TIPS, 4 h) were found to be insufficient for
28, and species with Pbf-protected arginine residues were observed in the
mass spectrum (Figure 3.2, left-hand spectrum). Treatment of the partially
protected crude peptide with the cleavage cocktail for a further 3 h gave fully
deprotected peptide thioester 24 (right-hand spectrum), alongside a single
serine deletion peptide.
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Figure 3.2: MALDI-TOF mass spectra of cleavage mixture for TFA deprotection of test
thioester 28 after 4 h (left-hand spectrum) and 7 h (right-hand spectrum). Various
partially deprotected peptides and/or deletion sequences are present in the first
spectrum, while after extended TFA treatment only a single serine deletion peptide
remains alongside the intended product (24, ASYRRITSSK-thioester) in the second
spectrum.
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3.3.2 Synthesis of thioester fragments for NCL
Having demonstrated the effectiveness of thioester generation using the
sulfonamide safety-catch linker, the next objective was to complete the
synthesis of fragment 7 (Scheme 3.1). Synthesis up to Ala-26 had previously
been achieved (and Arg deprotections optimized), therefore completion of
the fragment was expected to be unproblematic. Due to the occurrence
of deletions in the previous synthesis however, it was decided that double
couplings should be employed for all residues in the sequence. In addition,
selected residues were triple coupled‡ in anticipation of potential sequence
difficulty predicted using the Peptide Companion software (Section 2.1) and
through consideration of the occurrence of β-sheet regions and the deletions
observed previously.
An automated room temperature synthesis of CCL2(12-35) thioester (7)
was carried out as described, with Boc-Cys(Trt)-OH coupled as the N-
terminal amino acid. Linker alkylation, thiolysis and global deprotection were
performed as described. A second thioester, 29, was also synthesized with
Boc-Thz-OH coupled at the N-terminus in place of the Cys derivative. This
was done so that a version with masked N-terminal Cys would be available
if it was decided that a sequential (rather than convergent) ligation strategy§
should be adopted (vide infra).
Mass spectra showing thioesters 7 and 29 are given in Figure 3.3. A
small by-product peak is present in both corresponding to a single Gln or
Lys deletion – potentially indicative of difficulty at Gln-23, and which may be
eliminated by triple coupling at this residue.
3.4 Synthesis of C-terminal segment
As a result of the efforts to assemble CCL2 in a single SPPS run described
previously (Chapter 2), it was shown that synthesis up to Ala-53 (24-mer) is
achievable. The addition of a cysteine residue gives C-terminal fragment 9
(Scheme 3.1), hence the synthesis was repeated (using the same conditions:
automated MW-SPPS, polystyrene Wang resin) and extended to Cys-52, and
all of the peptide was cleaved from the resin. A mass spectrum confirming the
‡Triple couplings were used for the following residues: YNFTNRKISVQRLASYRRITSSK.
§Occurring in the C- to N-terminal direction (see Section 1.2.3).
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Figure 3.3: MALDI-TOF mass spectra of thioester fragment CCL2(12-35) (Xaa-
YNFTNRKISVQRLASYRRITSSK-thioester) incorporating N-terminal Cys (7, left-hand
spectrum) or Thz (29, right-hand spectrum). A small peak corresponding to a Gln or
Lys deletion is present in each spectrum.
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successful generation of peptide 9 is shown in Figure 3.4. The peptide was
purified via RP-HPLC and FPLC (see Section 4.2 and Experimental section).
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Figure 3.4: MALDI-TOF mass spectrum of C-terminal fragment 9 – CCL2(52-76),
CADPKQKWVQDSMDHLDKQTQTPKT.
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3.5 Summary
Significant progress has been made towards a total chemical synthesis of CCL2
using native chemical ligation. Two solid-phase methods of peptide thioester
synthesis have been investigated, and thioester fragment 7 (Scheme 3.1) was
successfully synthesized – along with Thz-masked counterpart 29 – using
the sulfonamide safety-catch approach. The alternative N-acylurea method –
utilizing Dawson’s Dbz linker – was successfully adapted for MW-SPPS using
the Alloc protection strategy developed by Mahto et al. While issues with Alloc
deprotection and linker cyclization need to be addressed, the technique was
used for the partial synthesis of fragment 8, representing the first reported use
of the Dawson Dbz linker for microwave-assisted SPPS. In addition, C-terminal
fragment 9 was synthesized on a suitable scale (∼160 mg) and purified for use
in the total synthesis.
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Peptide purification and
characterisation
The characterisation and purification of peptides carries with it potential
difficulties beyond those experienced for small organic molecules. Mass
spectrometric observation of peptide species can become less trivial with
increasing molecular weight, requiring the use of more suitable techniques
such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry and greater attention to sample preparation. In addition,
SPPS can generate numerous side products alongside the target peptide in
the form of chemically similar deletion sequences.37 The chromatographic
separation of these from the target is often based solely on subtle differences
in hydrophobicity, and therefore can also prove challenging.
The following sections outline some of the considerations that need to be
taken into account when using MALDI-TOF MS for peptide characterisation,
along with a description of the steps taken to purify the products of SPPS and
the optimization of parameters used for chromatographic separation.
4.1 The characterisation of synthetic peptides
using MALDI-TOF MS
MALDI-TOF mass spectrometry facilitates the analysis of heterogeneous
mixtures of large molecules90,91 and is therefore well suited to the analysis
of crude reaction products from SPPS. The MALDI ion source generates
primarily singly charged ions with no fragmentation, hence simplifying the
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interpretation of spectra obtained from samples containing complex mixtures
of different peptide sequences. Care must be taken when interpreting MALDI-
TOF mass spectra: while the technique has been shown to be useful for
reaction monitoring (vide supra), the intensity of a mass spectral peak is
highly dependent on the ionization efficiency of the corresponding peptide –
which in turn is affected by peptide composition and chemical environment.92
Therefore MALDI-TOF MS should only ever be used as a very rough indicator
of product purity.
The two mass spectra given in Figure 4.1 correspond to Fmoc-protected
(right-hand spectrum) and deprotected (left-hand spectrum) versions of the
peptide KQTQTPKT. As well as the dramatic difference in relative intensity
of the sodiated/unsodiated peaks between spectra, the observed by-products
are much less prominent for the Fmoc-protected form, suggesting that in
this case the protected peptide is perhaps more easily ionized. This example
highlights the fact that the apparent absence of impurities from a MALDI-TOF
MS spectrum can often give a false impression of crude product purity. Issues
relating to sample preparation and how this can affect the resulting spectrum
are discussed in the following section.
4.1.1 Sample preparation
The conditions used for sample preparation can dramatically affect the quality
of MALDI-TOF MS spectra. The choice of solvent can change which peaks
are observed in a spectrum, while the hydrophobicity of an analyte – and its
solubility in a particular solvent – can dictate whether the desired peptide is
observed in the spectrum at all. Care must be taken to ensure the peptide
dissolves adequately when preparing the sample solution – dissolving the
peptide in water should be the first step, with subsequent addition of a solvent
such as acetonitrile to make sure that any hydrophobic species present are
also dissolved. For particularly hydrophobic peptides a higher proportion of
organic solvent can be used, although solvents with a polarity lower than
water should ideally make up no more than 50% of the sample solution by
volume.93 Other organic solvents such as methanol or THF can also be tried
if results are not satisfactory with MeCN. The addition of 0.1% TFA was also
found to improve solvation for particularly insoluble peptides, and has been
shown to increase mass resolution and accuracy for MALDI-TOF MS.93
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Figure 4.1: MALDI-TOF mass spectra of the crude peptide KQTQTPKT, with N-
terminal Fmoc protection (right-hand spectrum) and without (left-hand spectrum). A
clear difference in the relative peak intensities can be seen between spectra.
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Figure 4.2 illustrates the effect solvent choice can have on the resulting
mass spectrum. The left-hand spectrum (taken from Figure 3.1, Section 3.2.1)
was collected from a sample prepared using MeCN as the organic solvent –
peaks corresponding to peptides 13 and 22 are observed. The sample used
for the right-hand spectrum was prepared using MeOH instead of MeCN.
Not only is the relative intensity of the peak corresponding to 13 much
higher, but the intensities for all peaks are at least 20 times higher than in
the first spectrum – potentially indicating that the corresponding peptides are
more soluble in methanol. The apparent increased prominence of impurities
in the second spectrum should also be noted. This comparison serves to
demonstrate the huge effect solvent choice and species solubility can have on
the prominence of peaks in MALDI-TOF mass spectra, while highlighting the
importance of trialling different sample preparation conditions before even
tentative conclusions about the success of a particular synthesis are inferred
from mass spectral data.
If no peaks (other than matrix/baseline noise) are observed, an amount of
solid larger than the standard 1 mg/mL should be used for sample preparation
– particularly for higher molecular weight targets, where the proportion of
target to impurities (and the amount of one peptide in a given sample mass)
becomes increasingly small. It is also vitally important to remove all small
organic by-products resulting from protecting group cleavage during TFA
treatment. These impurities can affect the quality of resulting mass spectrum
and therefore the crude product should be washed thoroughly in diethyl ether
to ensure only peptide species remain before MS sample preparation (see
Experimental section). A poor signal to noise ratio may also be improved by
desalting the crude peptide prior to analysis – special desalting pipette tips
or microcentrifuge tubes are commercially available and can be used for this
purpose.94
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Figure 4.2: MALDI-TOF mass spectra of the crude mixture of peptides 13 (without
Alloc group) and 22 (with Alloc). For the left-hand spectrum the sample was prepared
using MeCN/water, whereas for the right-hand spectrum MeOH/water was used.
The clear difference in peak intensities demonstrates the effect solvent choice during
sample preparation can have on the resulting spectra.
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4.2 Chromatographic purification of synthetic pep-
tides
Reversed-phase high-performance∗ liquid chromatography (RP-HPLC) is the
technique most commonly used for the routine purification of synthetic
peptides and proteins. In most cases the principle impurities are deletion
peptides - this is in contrast to recombinantly expressed protein, where
the crude product will often be present alongside a variety of (potentially
toxic6) cell-derived proteins of varying molecular weights in addition to other
unwanted cellular matter. Chromatographic methods such as immobilized
metal ion affinity chromatography (IMAC) and size-exclusion chromatography
(SEC) may be better suited to the purification of expressed protein, with RP
techniques used as a final ‘polishing step’ in the separation protocol. Thierry
et al. however reported the use of SEC as an initial purification step in their
attempts to obtain chemokines via total chemical synthesis, where preliminary
RP-HPLC separation failed.95 It was reasoned that heavy contamination of the
crude product with small organic by-products of protecting group cleavage
was to blame, thus SEC was used to remove these before HPLC purification.
The initial chromatographic separation of a number of crude peptides is
described in the following sections alongside a discussion of subsequent high
resolution purification steps and the optimization of conditions necessary for
effective separations.
4.2.1 Initial RP-HPLC separation of crude peptides
Chromatographic separation of crude synthesis products was performed using
a semi-preparative SB Analytical C-18 reversed-phase column (5.0 µm, 10.0
× 250 mm). A 30 minute gradient of 0-100% of solvent B was utilized for
initial analytical runs. It was found that these small-scale runs (∼1 mg loading)
facilitated peak assignment (using MALDI-TOF MS) and the optimization of
separation conditions prior to scale-up. Once the retention times of any peaks
of interest had been ascertained (and conditions optimized), only the gradient
region in which the peaks in question eluted was deemed important for scale-
∗‘High-performance’ (or high-pressure) refers to the fact that separations are carried out
at a higher pressure than with standard liquid chromatography. This enables the use of
shorter columns with a smaller stationary phase particle diameter, therefore allowing faster
separations to be a achieved with a higher resolution than normal.
72
Chapter 4. Peptide purification and characterisation
up, and a much steeper gradient was used to reach the point where fraction
collection could begin. An illustrative chromatograph – for the separation of
peptide 9 (Section 3.4) – is shown in Figure 4.3.
9
Figure 4.3: Chromatogram for HPLC separation of peptide 9 (CADPKQK-
WVQDSMDHLDKQTQTPKT) using a gradient of 0-100% B at a flow rate of 2 mL/min.
The solvent composition was as follows: A = 5% MeCN in 0.1% TFA, B = 95% MeCN
in 0.1% TFA (further details given in Experimental section). Using a small amount
of organic modifier in the A solvent improves wetting of the hydrophobic stationary
phase.96 Absorbance at 280 nm is plotted – the major peak observed corresponds
to 9 (m/z = 2929.9). While baseline resolution is not achieved, these conditions
were useful as a preliminary purification step prior to high resolution purification on
a smaller scale (vide infra).
4.2.2 High resolution FPLC purification
High resolution separations were carried out using an A¨KTAexplorer FPLC
system equipped with a high resolution SOURCE 15RPC ST 4.6/100 column
(reversed-phase). For analytical runs ∼0.5 mg in 0.5 mL of solvent A was
loaded onto the column per injection, and the separation was run with a
gradient of 0-100% solvent B in 20 column volumes at a flow rate of 2 mL/min.
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A standard H2O/MeCN/TFA solvent system was utilized initially, although it
was found that a basic buffer system was more suitable for the purification of
chemokine-derived sequences (vide infra).
While pH was found to be the parameter having the most significant
effect on selectivity, other conditions that were optimized in order to improve
resolution were flow rate and gradient duration. In the case of a poor
separation the gradient slope was first decreased, followed by the flow rate.
An FPLC chromatogram for the separation of crude peptide 9 is shown
in Figure 4.4, the peak corresponding to the target peptide (as confirmed by
MALDI-TOF MS) is marked with an asterisk (∗). It can be seen that the peaks
are sharper with a better separation than in Figure 4.3.
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Figure 4.4: Chromatogram for FPLC separation of ligation fragment 9 in basic
conditions (vide infra). A gradient of 0-80% was used (shown) at a flow rate of 1
mL/min. Absorbance at 280 nm is plotted and the peak corresponding to peptide
9 (m/z = 2929.7) is marked with an asterisk (∗). It can be seen that the resolution
achieved is significantly higher than for the previous separation (Figure 4.3).
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4.2.3 Optimization of solvent pH
Optimum buffer pH is one of the most important parameters to establish,
and pH optimization should be one of the first steps in FPLC method
development.96 Figure 4.5 shows an FPLC chromatogram for the C-terminally
amidated fragment CCL2(63-76) – SMDHLDKQTQTPKT-amide (30) – run in
an acidic solvent system (details given in figure caption). 30 was synthesized
via automated MW-SPPS on Rink amide AM resin (for linker structure
see Figure 2.2), and the crude product subjected to an preliminary HPLC
purification as detailed in the Experimental section. It can be seen that the
attempt at FPLC purification of the resulting material in acidic conditions is
unsatisfactory, as almost no peak separation is achieved (despite using a high
resolution column).
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Figure 4.5: Chromatogram for FPLC separation of peptide 30 in acidic conditions.
Solvent composition according to the manufacturer’s instructions: A = H2O with0.065% TFA, B = MeCN with 0.050% TFA (further details given in Experimental
section). A gradient of 0-100% was used (shown) at a flow rate of 2 mL/min.
Absorbance at 280 nm is plotted. It can be seen that the conditions utilized are
not sufficient for the resolution of individual peaks.
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The poor resolution achieved using the standard acidic buffer system
was thought to be due to the fact that chemokines (and chemokine-derived
fragments) are basic species, and as such they are liable to elute as tailing
peaks from reversed-phase columns at low pH.96 SOURCE 15RPC – being a
polymeric (polystyrene/divinyl benzene) medium – can be used for separations
performed at a pH well above neutral, and so it was hypothesized that
a separation under basic conditions may be more effective. A pH 9.0
Tris hydrochloride buffer system was trialled which dramatically improved
separations, with almost baseline separation being attained for peptide 30
(Figure 4.6).
-10
10
30
50
70
90
14 19 24 29 34 39
A
b
s
o
r
b
a
n
c
e
Volume /mL
A - 10 mM Tris HCl (pH 9.0)
B - 10 mM Tris HCl (pH 9.0), 60% MeCN

Figure 4.6: Chromatogram for FPLC separation of fragment 30 utilizing a basic buffer
system. Buffer composition according to the manufacturer’s instructions: A = 10
mM Tris HCl (pH 9.0), B = 60% MeCN in 10 mM Tris HCl (pH 9.0). A gradient
of 0-100% was used (shown) at a flow rate of 2 mL/min. Absorbance at 280 nm is
plotted and the major peak (corresponding to a Lys or Gln deletion, m/z = 1500.9) is
marked with an asterisk (∗). The resolution is greatly improved when compared with
the separation achieved in acidic conditions (Figure 4.5).
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As a result of these findings it is recommended that the FPLC purification
of chemokines and chemokine-derived peptide fragments should be carried
out using a basic buffer system.
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4.3 Summary
Protocols for the chromatographic purification of synthetic chemokine
fragments have been established. Semi-preparative RP-HPLC was found to
be useful for preliminary purification of the crude material on a large scale,
followed by high resolution FPLC purification. While the standard acidic
buffer system was initially trialled for FPLC separations, a basic (pH 9.0) Tris
hydrochloride buffer system proved to be superior for achieving decent peak
separation with the chemokine fragments described. Tris hydrochloride is
a non-volatile buffer component and hence must be removed using dialysis
from the final product – this is impractical for individual column fractions,
and the presence of Tris was found to reduce the sensitivity of MALDI-TOF
MS analysis during peak assignment. For this reason a volatile basic buffer
component such as ammonium acetate96 should be investigated for basic
separations.
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Structure elucidation of small
molecule chemotaxis inhibitors
Structural data is crucial for understanding the mechanism of action of any
small molecule ligand found to modulate the activity of a cell signalling
protein or enzyme. In the search for potential anti-inflammatories targeting
CCL2-mediated processes, the three-dimensional structure and conformation
of a bioactive lead compound is needed in order to fully understand the
interactions underpinning its activity. The most powerful technique for
structure elucidation is single crystal X-ray diffraction – although NMR
spectroscopy can also provide a wealth of structural information for a
particular ligand. Once 3D structures have been obtained for the protein and
ligand, so-called ‘molecular docking’ can be used to investigate protein-ligand
interactions computationally.97–99 During the docking process the optimum
‘pose’ of the ligand in a binding site on the protein is sought, which can then
be used as a model of the conformation of the ligand in the real binding site.
The ‘correctness’ of a particular pose can be evaluated in silico by running
molecular dynamics simulations or analysing how well the ligand and protein
‘fit’ together from a purely geometric perspective (the method used depends
on the docking approach taken). The end result is a computationally-generated
model of how the lead compound interacts with its binding site on the protein,
and using this information structural features of the ligand can be proposed
that are particularly important for binding.
The structure elucidation of three small molecule inhibitors of CCL2-
mediated chemotaxis – with a view to investigating CCL2-inhibitor interactions
using molecular docking – is described in the following sections.
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5.1 Background
A number of synthetic analogues (31, 32 and 33) of natural product 34
(Figure 5.1) – isolated from the fungus Leptoxyphium sp.100 – were assayed
for inhibitory activity against CCL2-mediated monocyte chemotaxis in vitro
(Mahsa Saleki and Simi Ali, Newcastle University).101 While compounds 32
and 33 were found to be more potent inhibitors than the natural product
(34), Western blots showed that stimulation with 32 and 33 did not reduce
ERK1/2 phosphorylation – a marker for receptor activation – in the model cell
line. This suggests that the inhibitors are not receptor antagonists, and that
the mechanism of inhibition does not involve disruption of the interaction
between CCL2 and its receptor directly. It was therefore proposed by Saleki
et al. that the inhibitory activity of the dipeptides described may be due
to an interaction with CCL2 itself, perhaps resulting in the disruption of
chemokine dimerization. The exact role of CC chemokine oligomerization
in the regulation of leukocyte trafficking is still not fully understood,26 and it is
hoped that a clearer understanding of chemotaxis inhibition – with reference to
dimer disruption – may lead to a more precise description of how chemokine
dimerization plays a part in this regulatory process. Molecular docking can
be used to investigate the nature of the CCL2-inhibitor interactions proposed,
although a three-dimensional structure for each ligand is required before this
can be carried out. Dipeptide 31 did not show inhibitory activity despite being
closely related in structure to the other compounds.
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Figure 5.1: Natural product 34 and synthetic analogues 31, 32 and 33. Compound
34 has previously been shown to inhibit CCL2-mediated monocyte chemotaxis.100,101
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5.2 Crystallization
In order to characterise a molecule via single-crystal X-ray diffraction,
ordered crystals of the compound of interest must first be obtained. The
simplest method involves crystallization from a supersaturated solution of the
compound in a solvent in which it has intermediate solubility. To obtain good
quality crystals the conditions should be optimized so that crystal formation
happens as slowly as possible. This ensures only a limited number of crystals
form (nucleation events are rare/ growth only occurs from a small number of
seed crystals), resulting in larger crystals with fewer defects or satellites.
If single crystals or crystalline material cannot be obtained from a single
solvent, the addition of an antisolvent (a solvent in which the compound is
insoluble/ has low solubility) may encourage an amorphous-crystalline phase
transition. An initial solvent screen – which can be carried out on a microscope
slide using < 1 mg of material – is essential in order to assess the solubility
of the compound in a range of solvents. Crystalline and amorphous material
can be distinguished via observation under a microscope fitted with a pair of
crossed polarizing filters due the fact that a crystalline sample will appear bright
against a dark background. The tendency of a particular solvent to promote
a transition to the crystalline phase is of crucial importance, and it is these
solvents which should be used in subsequent crystallization experiments.
Crystalline material was initially obtained via recrystallization of dipeptide
31 from ethanol. Addition of a small amount of ethanol to a saturated solution
of 31 in acetonitrile – with gentle heating to ensure complete dissolution
followed by seeding – yielded diffraction-quality crystals after 1-2 days.
Crystals of 32 were obtained from toluene using the same method.
Compound 33 proved more difficult to crystallize, remaining amorphous
in a wide range of solvents. Eventually crystalline material was obtained
via recrystallization from a saturated ethanol solution using diethyl ether
as an antisolvent, although the crystals were not single. In order to allow
crystallization to occur more gradually, a vapour diffusion setup was utilized
in which an open vial containing a saturated solution of 33 was placed within
a larger (sealed) vessel containing (more volatile) diethyl ether, allowing slow
diffusion of the antisolvent into the compound solution. A small number of
crystals suitable for testing were obtained using this method.
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5.3 Data collection
X-ray diffraction data were collected at 100 K on a Bruker MicroStar
diffractometer using a Cu-rotating anode. A photograph of a crystal of 33
mounted on the goniometer head of the diffractometer is shown in Figure 5.2.
Crystallographic data for compounds 31, 32 and 33 are summarized in
Table 5.1. The absolute configuration was confirmed by the Flack parameter
(given in the table).102
Unfortunately a complete data set could not be obtained for compounds
32 and 33 as data collection had to be aborted due to technical problems
(cryosystem failure). In addition, only a small number of reflections beyond
1 Å resolution were collected for 32 and 33 due to limited crystal quality.
For these reasons the overall completeness (∞ to 0.85 Å) reached only 70%
(Friedel pairs not merged).
A complete data set should be collected for each compound, and further
crystallization attempts are ongoing. Nevertheless the data were sufficient to
solve both structures and assign absolute configuration.
Figure 5.2: Crystal of compound 33 mounted on the diffractometer goniometer head
(glass fibre in Fomblin oil).
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Table 5.1: Crystallographic data for 31, 32 and 33.
Dipeptide 31 Dipeptide 32 Dipeptide 33
Empirical formula C14H16N2O3 C14H16N2O2 C14H15FN2O2Mr 260.29 244.29 262.28
T [K] 100 100 100
Crystal system Hexagonal Monoclinic Monoclinic
Space group P63 P21 P21
a [Å] 16.3840(3) 5.5875(7) 11.7856(6)
b [Å] 16.3840(3) 10.0300(14) 9.0051(4)
c [Å] 8.9875(2) 10.6734(15) 12.4478(6)
α [◦] 90.00 90.00 90.00
β [◦] 90.00 92.272(7) 109.1380(10)
γ [◦] 120.00 90.00 90.00
Resolution [Å] 0.843 0.849 0.868
V [Å3] 2089.34(7) 597.70(14) 1248.08(10)
Z 8 2 4
Z’ 1 1 2
ρcalc [mg mm−3] 1.209 1.271 1.061
µ [mm−1] 0.712 0.740 0.754
F(0 0 0) 800.0 229.0 397.0
Reflections collected 12958 2832 6500
Independent reflections 2456 1361 2794
Data/restraints/parameters 2456/1/183 1361/1/163 2794/16/343
Completeness (∞ to 0.85 Å) [%] 96.0 69.7 70.1
R1, wR2 [I > 2σ(I)]a 0.0228, 0.0669 0.0499, 0.1266 0.0428, 0.1267
R1, wR2 [all data]a 0.0228, 0.0670 0.0503, 0.1276 0.0429, 0.1273
Largest diff. peak, hole [e Å−3] 0.12, -0.14 0.28, -0.27 0.28, -0.19
Flack parameter102 0.04(14) 0.3(3) 0.16(16)
a R-factors calculated using
R1 =
∑ ||F0| − |FC||∑ |F0| and wR2 =
√∑
w(F20 − F2C)2∑
w · F40
where w is a weighting term.
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5.4 Molecular structure and packing
5.4.1 Cyclo(L-Tyr-D-Pro)
The molecular structure of dipeptide 31 is shown in Figure 5.3. The 6-
membered diketopiperazine ring adopts a shallow boat conformation, while
the bicycle as a whole exists as the twist-boat conformer. The boat
conformation of the 6-membered ring is characteristic of proline-containing
2,5-DKP compounds. In contrast, the 6-membered ring in monocyclic DKPs
is highly flexible and can adopt a twist-boat or planar conformation.103–105 The
phenol side chain of 31 is folded towards the DKP ring system – this is in
contrast to the conformers observed for dipeptides 32 and 33, for which the
side chain is extended (vide infra).
A molecular dynamics simulation of the enantiomer of 31 carried out by
Li et al.106 gave an optimized geometry almost identical to the one presented,
suggesting that the folded conformation observed is not simply an artefact of
intermolecular packing interactions within the crystal. It has been suggested
that nonsteric factors play a role in dictating the conformational distribution
for such systems, and that the folded conformer may predominate due to
interaction of the aromatic ring with the pi system of the amide bond.107
An X-ray diffraction study of cyclo(L-Tyr-L-Pro) found that the diastereomer
also exists as the folded conformer, although the DKP ring adopts a flattened
chair conformation in this case.108 This suggests that it is not simply the
difference in proline configuration between 31 and the other synthetic
dipeptides that causes it to exist uniquely in the folded conformation.
The crystal packing arrangement is shown in Figure 5.4. Interestingly, the
structure is composed of helices which span the length of the crystal and
associate via O19−H19···O11 hydrogen bond contacts (side chain hydroxyl
and ring carbonyl). Molecules of the solvent (MeCN) are interspersed
amongst these channels, which are arranged in parallel within the crystal
structure. Within each helix the individual molecules interact by N4−H4···O10
hydrogen bonds. A single helix along with the solvent of crystallization
is shown in Figure 5.5 – the helix is left-handed and has 6 molecules per
turn. Electron density occurring within the channels themselves (and which
could not be assigned) was thought to be due to the presence of further
residual disordered solvent.∗ 2,5-Diketopiperazines are molecules of interest
∗Solvent masking was used during structure refinement (see Experimental section).
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Figure 5.3: Molecular structure of compound 31 showing 50% probability anisotropic
displacement ellipsoids.
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in crystal engineering,109,110 and the X-ray diffraction data presented here
reveal a novel, highly ordered supermolecular structure of potential use in
the development of materials that exhibit nonlinear optical properties and
electrical superconductivity.105
Figure 5.4: Crystal packing arrangement for compound 31. The structure is
comprised of hexagonal channels surrounded by ordered molecules of acetonitrile.
Residual disordered solvent (MeCN) appears to be present inside the channel (see
text).
5.4.2 Cyclo(L-Phe-L-Pro)
The molecular structure of 32 is shown in Figure 5.6. The 6-membered DKP
ring adopts a shallow boat conformation as previously observed, although
the phenylalanine side chain is extended unlike the tyrosine side chain in the
folded conformer observed for compound 31. The packing arrangement is
stabilized by N4−H4···O10 hydrogen bonding.
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Figure 5.5: Helical arrangement of molecules in the crystal packing observed for
compound 31 (ordered solvent molecules are shown). A N4−H4···O10 hydrogen
bond stabilizes the helix.
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Figure 5.6: Molecular structure of compound 32 showing 50% probability anisotropic
displacement ellipsoids.
5.4.3 Cyclo(L-p-FPhe-L-Pro)
The diffraction data for 33 reveal that the dipeptide crystallizes with two
molecules in the asymmetric unit (Z’ = 2). Crystal structures with Z’ >
1 are rare, and the phenomenon often occurs for chiral molecules that
pack awkwardly with each other in the solid state.111,112 Current opinion is
divided as to whether these structures are thermodynamic minima or simply
metastable forms obtained under kinetic conditions, and discussions of the
nature and reasons for their formation are ongoing.113 The asymmetric unit is
shown in (Figure 5.7). For both molecules the DKP ring adopts a shallow
boat conformation with the side chain extended. The 5-membered ring
incorporating C27 is disordered, and consequently the bicyclic ring system
exists as both the chair (C27A) and boat (C27B) conformer.
A similar 2,5-DKP compound was found to have Z’ > 1 in an X-ray
crystallographic study by Budesinsky et al.114 Data collection was carried
out at both 150 K and room temperature, with reversible changes in crystal
lattice parameters and packing geometry occurring during the transition. In
light of this result the authors suggested that the reason for Z’ > 1 in the low-
temperature structure was likely to be kinetic. Structural data for compound
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33 were collected at ∼100 K and therefore it is conjectured that the structure
obtained is a metastable form.
The apparent ‘packing frustration’ and inability of the side chain fluorine to
act as a hydrogen bond donor may account for the relatively low density113 of
33 (see Table 5.1), and the difficulty experienced during attempts to crystallize
it in comparison with the tyrosine derivative (32).
Figure 5.7: Molecular structure of compound 33 showing 50% probability anisotropic
displacement ellipsoids (with the exception of C27, which could not be refined
anisotropically).
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5.5 Summary
Diffraction-quality single crystals were obtained for two inhibitors of in vitro
monocyte chemotaxis (32 and 33), in addition to a third structurally similar
compound (31) that exhibited no inhibitory activity. X-ray diffraction data were
collected successfully for all three compounds and their structures solved. It
is suggested that the lack of inhibitory activity for 31 is due to the dipeptide
existing in a folded conformation, while the inhibitors in question both have an
extended aromatic side chain. This may be due to the presence of the tyrosine
hydroxyl (absent from the inhibitor structures), which may play a role in the
purported nonsteric interactions previously discussed. The fact that the natural
product exhibits inhibitory activity (despite possessing a hydroxyl group) can
potentially be accounted for by considering the effect of steric hindrance from
the ring chlorines, which may prevent occurrence of the folded conformation
– although a crystal structure of this molecule is required in order to further
elucidate the nature of this interaction.
Ligand structural data are required in order to carry out molecular docking
studies, and to establish whether chemokine-DKP interactions may play a part
in chemotaxis inhibition. These results will therefore not only be relevant to
investigations of the 2,5-DKP scaffold for anti-inflammatory drug discovery,
but will also find use in continued efforts to elucidate the role of chemokine-
chemokine and chemokine-receptor interactions in CCL2-mediated monocyte
chemotaxis.
90
Chapter 6
Conclusions and future work
Significant progress has been made towards the total chemical synthesis of
the chemokine CCL2. In addition, the structures of a number of inhibitors
of CCL2-mediated chemotaxis have been obtained via single crystal X-ray
diffraction.
Attempts to synthesize the whole chemokine in one piece using Fmoc
SPPS were hindered by the on-resin hydrophobic aggregation of the peptide
during elongation. In order to avoid aggregation, the PEG-based ChemMatrix®
polymer support was investigated in combination with pseudoproline dipep-
tides as an alternative to conventional polystyrene-based resin. It was decided
however that a synthesis involving the ligation of smaller fragments of CCL2
in solution might be a more promising route, and the work already completed
showed that microwave-assisted SPPS using conventional polystyrene Wang
resin was the most effective method for the generation of acid fragments of
up to ∼40 residues in length.
A total chemical synthesis involving the native chemical ligation of four
fragments of CCL2 was proposed (Section 3.1), and the synthesis of two of
the required fragments – the C-terminal peptide acid and a peptide thioester
– has been completed. Room temperature SPPS using the sulfonamide safety-
catch linker was found to be effective for producing the thioester, while the
peptide acid was synthesized via MW-SPPS using polystyrene Wang resin.
Versions of the thioester with and without the N-terminal cysteine masked as
a thiazolidine have been synthesized for potential use in a sequential or fully
convergent ligation strategy respectively (should the former be required). The
Dawson Dbz linker was also investigated as a method of generating peptide
thioesters, and progress towards a third fragment has also been made. While
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‘over-acylation’ of the Dbz moiety proved to be an issue for microwave-
assisted syntheses initially, orthogonal protection of the linker eliminated this
problem resulting in the first reported use of the Dawson Dbz linker for MW-
SPPS.
Protocols for the purification of synthetic CCL2-derived sequences using
RP-HPLC and high resolution FPLC have been developed, and the peptide
acid fragment described has been successfully purified. It was found that
separations of basic chemokine fragments were more effective when carried
out using a Tris buffer at high pH. Tris hydrochloride is a non-volatile buffer
component however, and the use of a more volatile compound such as
ammonium acetate may allow more facile removal from column fractions,
increasing the sensitivity of MALDI-TOF MS analysis. The development of
purification protocols for the remaining peptide thioesters is also necessary.
Once all the required ligation fragments have been synthesized and
purified, suitable conditions for ligations, correct folding and oxidation15 of
the chemokine will be investigated. It is anticipated that a combination of RP-
HPLC, FPLC and SEC will be utilized in the purification of the complete protein.
Upon obtaining purified CCL2, biological testing (chemotaxis and calcium
mobilization assays15,101) will be used to verify that the protein obtained is
the desired product and that it is folded correctly. Circular dichroism (CD)
spectroscopy will also be used to confirm correct folding.
Alongside the synthetic work, single crystals of three synthetic analogues
of a naturally occurring CCL2 inhibitor were obtained. X-ray diffraction data
were collected and molecular structures for the three compounds successfully
determined. These will be useful for future molecular docking studies, with
the next step being the use of a pocket finding algorithm115 to identify potential
ligand binding sites on the surface of CCL2 using existing crystal structure data
for the protein.15,61 The inhibitor crystal structures can then be docked with
each of the candidate sites on the surface of CCL2 in order to determine for
which of these the binding affinity would be highest. Isothermal titration
calorimetry (ITC) can be used to quantify the strength of this interaction. A
binding site occurring at the dimerization interface would lend support to
the hypothesis that the inhibitory activity of the compounds described is due
to CCL2 dimer disruption. Cocrystallization of the CCL2 molecule with the
inhibitors discussed would allow detailed examination of the protein-ligand
interactions involved via X-ray diffraction experiments.
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When complete, the total chemical synthesis of CCL2 will enable the
generation of site-specifically labelled versions of the chemokine which will
be extremely valuable for use in biomedical research. As well as enabling
the facile production of fluorescently labelled and/or mutant chemokine
for use in biological assays, a disulphide-bonded obligate dimer26 can be
chemically synthesized, which could be used in cell-based studies with the
aim of further elucidating the role of CCL2 dimerization with regards to
chemotactic activity. The formation of a covalent dimer may also be possible
using Cu(I)-catalysed azide-alkyne ‘click’ cycloaddition to link azide- and
alkyne-modified CCL2 monomers,116 allowing nonsymmetric labelling41 of the
dimer. Further characterisation of the monomer-dimer dynamic equilibrium
may be accomplished through a Fo¨rster resonance energy transfer (FRET)
experiment117,118 – this requires two sets of monomer each labelled with a
different chromophore, which will be readily accessible via chemical synthesis.
Finally, a synthetic route will enable the site-specific incorporation of PTMs,
which will be utilized to investigate CCL2 chemokine nitration, a process
which regulates leukocyte infiltration in tumours and is therefore relevant to
drug research in the field of cancer immunotherapy.119
It can be seen that the protein tools accessible using total chemical
synthesis – as well as the small molecule ligands characterised – will be
extremely useful for research in the field of chemokine immunobiology. Not
only will these tools facilitate the investigation of the CCL2 oligomerization
process, but also the complex role of PTMs in the regulation of the immune
response. More generally, the techniques described will find broad application
in the field of chemical protein synthesis as a whole, allowing access to a
larger range of proteins, thus enabling the detailed characterisation of their
interactions in living systems.
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Experimental
7.1 Solid-phase peptide synthesis
All reagents were purchased from Sigma-Aldrich unless otherwise specified.
Peptide synthesis grade DMF was purchased from AGTC Bioproducts (Hessle,
UK) and amino acid derivatives were purchased from CEM, Novabiochem
(Merck) or AGTC. HBTU was purchased from CEM, TBTU from AGTC and
PyBOP® from Apollo Scientific (Stockport, UK). All resins were purchased
from Novabiochem with the exception of ChemMatrix®, which was purchased
from Sigma-Aldrich.
Fmoc SPPS procedures are detailed in the following sections. Fritted
polypropylene reaction vessels were used for all manual reactions and resin
swelling, with DMF as the reaction solvent. For peptide couplings HBTU, TBTU
or PyBOP® was used as the activator. Amino acid side chain functionality
was protected as follows: Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-
Asp(tBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(tBu)-OH,
Fmoc-His(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-
OH, Fmoc-Trp(Boc)-OH and Fmoc-Tyr(tBu)-OH. Fmoc deprotections were
carried out using a 20% (v/v) solution of piperidine in DMF. Pre-swelling of
the resin was carried out in DCM/DMF (1:1) for a minimum of 1 h (overnight
preferred), followed by washing with DMF. The resin was shrunk in diethyl
ether before storage and to remove DMF in preparation for TFA cleavage.∗
Peptide-resin was stored at −18 ◦C.
∗It should be noted that ChemMatrix®resin swells in MeOH, which is conventionally used
for shrinking polystyrene-based supports.73
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7.1.1 Automated Fmoc SPPS
Automated SPPS was carried out on a CEM Liberty1 single-channel microwave
peptide synthesizer equipped with a Discover microwave unit. All reactions
were carried out using the 30 mL PTFE reaction vessel, with microwave heating
and agitation by bubbling nitrogen. Couplings were carried out using a 5-fold
excess of Fmoc-protected amino acid, activator (10 equiv) and DIPEA (20
equiv, 2 M solution in NMP) unless otherwise stated.† For double and triple
couplings the reaction vessel was drained after each cycle and fresh reagents
were added.
Microwave-assisted
Microwave couplings at 0.05 mmol scale were carried out for 10 min at 75 ◦C
and 20 W power unless otherwise stated. Cys and His residues were coupled
at low temperature: 10 min at room temperature followed by 10 min at 50 ◦C
(20 W). Arg residues were double coupled, with the first coupling carried out
for 45 min at rt followed by 5 min at 75 ◦C (20 W), and the second using
the standard microwave conditions given. The Fmoc group was removed by
a single treatment with piperidine solution at 75 ◦C (35 W) for 3 min. For
0.1 mmol scale syntheses the power was increased to 25 W for couplings and
45 W for deprotections.
Room temperature
Couplings were carried out at room temperature for 60 min. The Fmoc group
was removed by two successive treatments with piperidine solution (5 min
then 10 min).
7.1.2 Manual microwave-assisted Fmoc SPPS
Manual SPPS was carried out in fritted polypropylene reaction vessels using
the Discover SPS system. Couplings and deprotections were carried out
using the conditions for automated MW-SPPS already described (vide supra).
†N.B. For syntheses at 0.05 mmol scale the mass of activator calculated by the Liberty1
software should be halved in order to give the correct number of equivalents when making
up the activator solution. This is especially important for HBTU and TBTU, as uronium type
coupling reagents can cap the peptide N-terminus if used in excess.
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Efficient mixing during the synthesis was achieved using a magnetic stirrer bar
(without nitrogen agitation). The success of each coupling/deprotection step
was confirmed using the qualitative monitoring protocols described below.
7.1.3 Alloc protection and loading of Dbz resin
The Dawson Dbz linker was Alloc protected and loaded using the procedure
described by Mahto et al.83 3-(Fmoc-amino)-4-aminobenzoyl (Dawson Dbz)
AM resin was first treated with allyl chloroformate (10 equiv) and DIPEA (1.0
equiv) in DCM (3 mL) for 24 h with agitation. The resin was washed with DCM
(3 × 5 mL) and DMF, and the linker deprotected manually with two piperidine
treatments at room temperature (as described previously in procedure 7.1.1).
After thorough washing with DMF, the resin was treated with Fmoc-Ile-OH
(15 equiv), HATU (13.5 equiv) and DIPEA (27 equiv) (1:0.9:1.8) in DMF (3
mL), and agitated for 1 h at room temperature. The solvent was removed
and the coupling step repeated. The resin was washed with DMF and the
remaining unreacted amine groups were capped via treatment with a 20%
(v/v) solution of acetic anhydride in DMF for 30 min.
7.1.4 Qualitative tests for the presence of free amines
TNBS test
The TNBS test was used to confirm the presence of primary amines during
SPPS.74 Approximately 10 resin beads were added to a microcentrifuge tube
containing 3 drops of a 1% (w/v) solution of 2,4,6-trinitrobenzenesulfonic acid
(TNBS) in DMF, and 3 drops of a 10% (v/v) solution of DIPEA in DMF. A
positive result (presence of primary amine) was indicated by a red colouration
of the beads, whereas a grey/yellow colouration remained in the case of a
negative result. Observation of the beads under a microscope was used to
identify colouration of the bead interior that could not be detected with the
naked eye.
Acetaldehyde/chloranil test
The acetaldehyde/chloranil test was used to confirm the presence of secondary
amines during SPPS.75 Approximately 10 resin beads were added to a
microcentrifuge tube containing 3 drops of a 2% (w/v) solution of chloranil
97
Towards a total chemical synthesis of human CCL2
in DMF, and 3 drops of a 2% (v/v) solution of acetaldehyde in DMF. A
positive result (presence of primary or secondary amine) was indicated by
a dark blue/green colouration of the beads, whereas the resin remained
colourless/yellow in the case of a negative result. Observation of the beads
under a microscope was used to identify colouration of the bead interior that
could not be detected with the naked eye. Reagent solutions were not kept
any longer than one month.
7.1.5 Cleavage of peptides from acid-labile resins
Peptide-resin was treated with 0.95 mL TFA and 0.05 mL deionized water, with
0.05 mL TIPS as a scavenger for 3-4 h at room temperature (values were tripled
when the mass of resin was greater than 100 mg). Longer cleavage times were
used for arginine-containing peptides. The resin was then removed by filtration
and the filtrate split into two portions which were each added dropwise to 45
mL of ice-cold diethyl ether. After centrifugation the supernatant was removed
and the pellets resuspended in fresh ether and centrifuged again. Following
further centrifugation, the supernatant was discarded. For cleavages where the
mass of peptide was deemed to be too small for precipitation/centrifugation to
be feasible the TFA was first removed under vacuum before precipitation using
ether and decanting of the liquid (followed by subsequent ether washes). The
resulting solid peptide was dissolved in deionized water and lyophilized. For
hydrophobic sequences a small amount of acetonitrile was added (< 50% v/v)
in the event of poor solubility (water and MeCN containing 0.1% TFA were
also used to improve solubility for particularly insoluble peptides).
7.1.6 Cleavage of peptides from Dbz resin
Activation and cyclization83
Alloc-protected peptide-resin was first deprotected using the method detailed
below. The resin was then treated with p-nitrophenylchloroformate (5 equiv)
in DCM (2.5 mL) for 1 h with nutation at room temperature. The reaction
vessel was drained, the resin washed with DCM (3 × 5 mL) and DMF (3 ×
5 mL), and DIPEA was added in DMF (0.5 M). After agitation for a further 45
min the solvent was removed and the resin washed in DMF.
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Alloc deprotection83
Alloc-protected peptide-resin was swollen in DCM for 1 h and sparged with
argon for 5-10 s. PhSiH3 (20 equiv) and Pd(PPh3)4 (0.35 equiv) were added
in a small amount of DCM and the reaction was agitated for 30 min at room
temperature. The resin was then washed with DCM and DMF.
7.1.7 Cleavage of peptides from sulfonamide resin
Peptide-resin was treated with iodoacetonitrile (10 equiv) and DIPEA (10
equiv) in DMF (1 mL) for 24 h with agitation in a foil-wrapped reaction
vessel.87,120 The solvent was removed and the resin washed with DMF (3
× 5 mL), THF (3 × 5 mL) and DMF again. Ethyl 3-mercaptopropionate (50
equiv) and sodium thiophenolate (0.5 equiv) were then added in DMF (2
mL) and the reaction agitated for a further 24 h. After removal of the resin
beads via filtration, the resulting protected peptide was precipitated in excess
ice-cold diethyl ether (200 mL). The solution was chilled for 2.5 h and the
fine precipitate was isolated via filtration of the suspension through a glass
fibre filter. The filtrand was washed with a large amount of ice-cold ether
and global deprotection of the product was achieved via TFA treatment of the
filter/filtrand (procedure 7.1.5).
7.1.8 CCL2 fragments
CCL2(53-76), ADPKQKWVQDSMDHLDKQTQTPKT (6)
Synthesized via automated MW-SPPS (procedure 7.1.1) on low loaded Fmoc-
Thr(tBu)-Wang polystyrene resin (0.27 mmol/g substitution, 0.05 mmol scale).
Resin cleavage and deprotection using TFA was carried out according to
procedure 7.1.5 to afford fragment 6, MALDI-TOF mass: found m/z 2827.9
(M + H)+, calcd 2827.1 (M + H)+.
CCL2(52-76), CADPKQKWVQDSMDHLDKQTQTPKT (9)
Synthesized via automated MW-SPPS (procedure 7.1.1) on low loaded Fmoc-
Thr(tBu)-Wang polystyrene resin (0.27 mmol/g substitution, 0.10 mmol scale).
Resin cleavage and deprotection using TFA was carried out according to
procedure 7.1.5 to afford fragment 9 (158 mg, 54%), MALDI-TOF mass:
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found m/z 2929.8 (M + H)+, calcd 2930.3 (M + H)+. The crude product
was purified via HPLC (procedure 7.2.1) and FPLC (procedure 7.2.2), using a
flow rate of 1 mL/min over 30 column volumes for the latter.
CCL2(39-76), EAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT (35)
Synthesized via automated MW-SPPS (procedure 7.1.1) on low loaded Fmoc-
Thr(tBu)-Wang polystyrene resin (0.27 mmol/g substitution, 0.05 mmol scale).
Resin cleavage and deprotection using TFA was carried out according to
procedure 7.1.5 to afford fragment 35, MALDI-TOF mass: found m/z 4372.9
(M + H)+, calcd 4372.0 (M + H)+.
CCL2(42-51), IFKTIVAKEI-diaminobenzamide (22)
3-(Fmoc-amino)-4-aminobenzoyl (Dawson Dbz) AM resin (0.42 mmol/g
substitution, 0.03 mmol scale) was first Alloc protected, loaded with Fmoc-Ile-
OH and capped according to procedure 7.1.3. The peptide was synthesized
on the Alloc-protected resin via automated MW-SPPS (procedure 7.1.1), with
Boc-Ile-OH coupled as the N-terminal amino acid. Alloc deprotection and
cyclization of the linker were then carried out according to procedure 7.1.6,
and subsequent TFA treatment (procedure 7.1.5) resulted in cleavage from the
resin and global deprotection to afford Alloc-protected diaminobenzamide 22
(3 mg, 9%), MALDI-TOF mass: found m/z 1294.7 (M + H)+, calcd 1295.6 (M
+ H)+.
CCL2(26-35), ASYRRITSSK-thioester (24)
Synthesized via automated SPPS at room temperature (procedure 7.1.1) on
H-Lys(Boc)-Sulfamylbutyryl NovaSyn® TG resin (0.2 mmol/g substitution,
0.03 mmol scale), with Boc-Ala-OH coupled as the N-terminal amino acid.
Linker activation and thiolysis were carried out according to procedure 7.1.7,
and global deprotection of the product (procedure 7.1.5) with an extended
cleavage time of 7 h afforded thioester 24, MALDI-TOF mass: found m/z
1284.6 (M + H)+, calcd 1285.5 (M + H)+.
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CCL2(12-35), Cys-YNFTNRKISVQRLASYRRITSSK-thioester (7)
Synthesized via automated SPPS at room temperature (procedure 7.1.1) on H-
Lys(Boc)-Sulfamylbutyryl NovaSyn® TG resin (0.2 mmol/g substitution, 0.03
mmol scale). Double couplings were used for all residues, except for those
which were triple coupled (given in Section 3.3.2) in anticipation of difficult
couplings predicted by the Peptide Companion software.66 Boc-Cys(Trt)-OH
was triple coupled manually as the N-terminal amino acid under the conditions
used for previous couplings. Linker activation and thiolysis were carried
out according to procedure 7.1.7, and global deprotection of the product
(procedure 7.1.5) with an extended cleavage time of 7 h afforded thioester 7,
MALDI-TOF mass: found m/z 3008.0 (M + H)+, calcd 3009.5 (M + H)+.
CCL2(12-35), Thz-YNFTNRKISVQRLASYRRITSSK-thioester (29)
Synthesized via automated SPPS at room temperature (procedure 7.1.1) on H-
Lys(Boc)-Sulfamylbutyryl NovaSyn® TG resin (0.2 mmol/g substitution, 0.03
mmol scale). Double couplings were used for all residues, except for those
which were triple coupled (given in Section 3.3.2) in anticipation of difficult
couplings predicted by the Peptide Companion software.66 Boc-Thz-OH was
triple coupled manually as the N-terminal amino acid under the conditions
used for previous couplings. Linker activation and thiolysis were carried
out according to procedure 7.1.7, and global deprotection of the product
(procedure 7.1.5) with an extended cleavage time of 7 h afforded thioester 29,
MALDI-TOF mass: found m/z 3019.7 (M + H)+, calcd 3020.5 (M + H)+.
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7.2 Peptide purification and characterisation
7.2.1 Reversed-phase high-performance liquid chromatog-
raphy (RP-HPLC)
Crude peptides were purified using a Speck and Burke Analytical C-18 column
(5.0 µm, 10.0 × 250 mm) attached to a PerkinElmer Series 200 LC Pump and
785A UV/Vis Detector. A linear gradient of 0-100% B (solvent A = 5/95/0.1
MeCN/H2O/TFA; B = 95/5/0.1 MeCN/H2O/TFA) over 30 min with a flow rate
of 2 mL/min was used for separations unless otherwise specified. Absorbance
data were collected at 280 nm. 0.5 mL of a 1 mg/mL solution was injected
for analytical runs, from which selected peak fractions were lyophilized and a
mass assigned using MALDI-TOF MS. For preparative runs, concentrations of
up to 20 mg/mL (0.5 mL) were injected and peak fractions of interest pooled
and lyophilized. The peptide solution was centrifuged before injection to
remove undissolved material.
7.2.2 Fast protein liquid chromatography (FPLC)
High resolution purification was carried out using an A¨KTAexplorer FPLC
system equipped with a SOURCE 15RPC ST 4.6/100 column (15 µm, 4.6
× 100 mm) (GE Healthcare). A linear gradient of 0-100% B (solvent A = 10
mM Tris HCl, pH 9.0; B = 60% MeCN in 10 mM Tris HCl, pH 9.0) over 20
column volumes with a flow rate of 2 mL/min was used for separations unless
otherwise specified. The fraction size was set at 1 mL and absorbance data
were collected at both 220 and 280 nm. 0.5 mL of a 1 mg/mL solution was
injected per run. The peptide solution was centrifuged before injection to
remove undissolved material.
7.2.3 Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS)
MALDI-TOF mass spectra we collected using an Autoflex II ToF/ToF mass
spectrometer (Bruker Daltonik GmBH) equipped with a 337 nm nitrogen
laser. Peptides were dissolved in 1:1 deionized water/MeCN for MS analysis
(solvents containing 0.1% TFA were used for particularly insoluble analytes).
Sample solution (1 mg/mL) was mixed with matrix solution (α-cyano-4-
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hydroxy-cinnamic acid, ∼50 mg/mL) in a ratio of 1:9, and 1 µL of the resulting
solution spotted onto a metal target and placed into the MALDI ion source.
Reflectron mode was used for molecules with m/z > 4000. MS data was
processed using FlexAnalysis 2.0 (Bruker Daltonik GmBH).
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7.3 Crystallography
7.3.1 Crystallization
Cyclo(L-Tyr-D-Pro) (31)
A saturated solution of dipeptide 31 was prepared in acetonitrile with gentle
heating. A small amount of ethanol was added to ensure complete dissolution
of the solid, and the solution was seeded with additional crystalline material.
Diffraction-quality crystals of 31 were obtained overnight.
Cyclo(L-Phe-L-Pro) (32)
Crystals of 32 were obtained using the same method as for dipeptide 31, but
using toluene as the solvent.
Cyclo(L-p-FPhe-L-Pro) (33)
A vapour diffusion setup was utilized comprising a open vial containing a
saturated solution of 33 in ethanol, placed inside a larger sealed vial containing
the antisolvent (diethyl ether). Crystals were obtained within 1 week.
7.3.2 Data collection
Crystallographic data for both compounds were collected on a Bruker
MicroStar diffractometer using a Cu-rotating anode, equipped with Helios
mirror optics as a monochromator and a Platinum 135 CCD detector. The
crystals were flash-cooled to 100 K during data collection using a cold nitrogen
gas stream. Measurements were performed using Cu Kα radiation (λ =
1.5417). All data were integrated and scaled using SAINT (Bruker, 2000).
7.3.3 Structure solution and refinement
The structures were solved by direct methods (SHELXS-97) and refined by
least squares methods against F2 (SHELXL-97).121 All non-hydrogen atoms
were refined with anisotropic displacement parameters and all hydrogen
atoms were unambiguously identified and refined isotropically on calculated
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positions using a riding model. Molecular graphics were created using Olex2
software.122
An electron density peak (corresponding to approximately 4 electrons)
present after structure refinement for compound 31 could not be assigned
an atom type, and was thought to be a result of residual disordered solvent
occupying the channel formed by packing of the dipeptide around a central
axis. Refinement was improved by using Olex2 solvent masking.123
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Portions of the work described here were presented at the British Biophysical
Society 2012 Conference, Durham University (poster and oral presentation),
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